≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Progressive systemic sclerosis

Endpoint Browser PheWeb

M13_PROGRESSIVE_SYSTEMIC_SCLEROSIS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — M34.0
  • Cause of death: ICD-10 — M34.0

2 out of 7 registries used, show all original rules.

168

4. Check minimum number of events

None

168

5. Include endpoints

None

168

6. Filter based on genotype QC (FinnGen only)

162

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 162 133 29
Unadjusted period prevalence (%) 0.04 0.05 0.01
Median age at first event (years) 54.81 52.75 64.23

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
168
Matched controls
1680
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M34.0
ICD-10 Finland
Progressive systemic sclerosis
+∞
243.0
168
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
38.4
132.3
124
115
C08CA05
ATC
nifedipine; systemic
42.4
131.5
95
50
M34.9
ICD-10 Finland
Systemic sclerosis, unspecified
+∞
109.8
93
*
P01BA02
ATC
hydroxychloroquine; oral
21.0
91.4
95
98
M34.1
ICD-10 Finland
CR(E)ST syndrome
267.7
78.7
75
5
L04AX01
ATC
azathioprine; systemic
26.5
63.9
48
25
L04AX03
ATC
methotrexate; systemic
13.0
59.8
77
103
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
11.6
43.3
53
64
M34.8
ICD-10 Finland
Other forms of systemic sclerosis
+∞
38.0
35
*
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
51.9
36.5
43
11
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
11.2
35.7
43
50
L04AA06
ATC
mycophenolic acid; systemic
46.1
34.8
42
12
XG410
NOMESCO Finland
Flow-volume spirometry
12.2
33.4
37
38
ZXD30
NOMESCO Finland
Difficulties in perfomrming procedure
12.2
30.2
33
33
XX9XE
NOMESCO Finland
Other ultrasound examination
78.4
29.1
32
5
I73.0
ICD-10 Finland
Raynaud syndrome
33.5
28.6
37
14
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
6.8
27.3
54
110
M34
ICD-10 Finland
Systemic sclerosis
305.4
26.5
26
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
5.4
26.4
104
387
G04BE03
ATC
sildenafil; oral
69.5
25.9
29
5
XPX04
NOMESCO Finland
Angioscopy
291.6
25.4
25
*
L88
ICPC
Rheumatoid/seropositive arthritis
9.1
24.3
33
44
GD1AA
NOMESCO Finland
Thorax X-ray examination
6.2
23.4
134
653
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
6.4
21.8
43
86
L04AA01
ATC
[U] ciclosporin
58.3
21.8
25
5
GD1AD
NOMESCO Finland
Thorax CT examination
7.6
21.5
34
54
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
26.5
19.8
27
12
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
6.3
19.2
37
72
TFC00
NOMESCO Finland
Catheterisation of right atrium or ventricle
50.3
18.7
22
5
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
16.3
18.6
30
22
H02AB06
ATC
prednisolone; systemic
4.7
18.0
127
670
TPH04
NOMESCO Finland
Cathetrisation of vein
4.1
17.5
69
242
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
4.2
17.1
62
204
J99.1*M34.8
ICD-10 Finland
Respiratory disorders in systemic: sclerosis
+∞
17.0
16
*
L94.0
ICD-10 Finland
Localized scleroderma [morphea]
53.2
16.4
19
*
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
13.2
16.0
28
25
I27.2
ICD-10 Finland
Other secondary pulmonary hypertension
175.7
15.8
16
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
13.8
15.7
27
23
Z01.8
ICD-10 Finland
Other specified special examinations
3.8
15.5
69
260
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
3.7
15.0
74
297
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
5.4
14.8
33
73
J01FF01
ATC
clindamycin; systemic
3.5
14.2
79
341
K21.0
ICD-10 Finland
Gastro-oesophageal reflux disease with oesophagitis
4.6
14.1
39
103
SPAT1148
SPAT
Treatment of chronic ulcer or burn
4.3
14.1
44
128
C02KX01
ATC
bosentan; oral
+∞
13.7
13
*
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
4.6
13.6
38
101
L01BA01
ATC
methotrexate; systemic
11.5
13.5
25
25
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
5.4
13.4
29
62
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.4
13.3
104
546
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.8
13.1
34
85
L04AD01
ATC
ciclosporin; systemic
17.3
13.0
20
13
H02AB07
ATC
prednisone; oral
3.9
12.8
47
153
L95
ICPC
Osteoporosis
5.3
12.7
28
61
M05BX04
ATC
denosumab; parenteral
4.7
12.0
31
77
C08CA02
ATC
felodipine; oral
4.5
11.9
33
87
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
15.1
11.8
19
14
7101A
ICD-9 Finland
Diffuse diseases of connective tissue, Systemic sclerosis[SCLERODERMA]
+∞
11.6
11
*
I27.0
ICD-10 Finland
Primary pulmonary hypertension
+∞
11.6
11
*
M01CC01
ATC
penicillamine; oral
+∞
11.6
11
*
XQ841
NOMESCO Finland
Examination of dermatosis with microscope
128.4
11.6
12
*
QC6S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in hand
128.4
11.6
12
*
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
13.2
11.2
19
16
ZX120
NOMESCO Finland
Intravenous
4.0
11.0
37
112
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.5
10.8
29
74
M05BA04
ATC
alendronic acid; oral
3.8
10.7
39
125
M35.1
ICD-10 Finland
Other overlap syndromes
117.0
10.5
11
*
K44.9
ICD-10 Finland
Diaphragmatic hernia without obstruction or gangrene
4.1
10.5
33
95
ND2BA
NOMESCO Finland
Hand and fingers extensive X-ray examination
12.4
10.3
18
16
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.3
10.2
47
175
A02BC01
ATC
omeprazole; systemic
2.9
9.8
71
342
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.8
9.8
34
105
E0000UV, ,
ATC
2.8
9.8
99
568
R06.0
ICD-10 Finland
Dyspnoea
2.8
9.7
73
358
G73.7*M34.8
ICD-10 Finland
Myopathy in scleroderma
+∞
9.5
9
*
R4120
NOMESCO Finland
Occupational therapy
4.5
9.4
25
63
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
4.9
9.4
22
50
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
14.8
9.4
15
11
TNX00
NOMESCO Finland
Puncture and needle biopsy of soft tissue, unspecified region
16.8
9.2
14
9
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
25.7
9.0
12
5
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
4.2
9.0
26
70
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
4.7
9.0
22
52
TGC00
NOMESCO Finland
Bronchial lavation
8.4
8.9
19
25
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
4.9
8.9
21
48
M05BA07
ATC
risedronic acid; oral
7.1
8.8
21
33
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.8
8.8
63
299
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
21.4
8.6
12
6
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
3.9
8.5
27
78
RT172, ,
NOMESCO Finland
+∞
8.4
8
*
C02KX04
ATC
macitentan; oral
+∞
8.4
8
*
M35.8
ICD-10 Finland
Other specified systemic involvement of connective tissue
+∞
8.4
8
*
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
7.5
8.3
19
28
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
4.6
8.3
21
51
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
3.5
8.3
32
106
UGC12
NOMESCO Finland
Flexible bronchoscopy
4.1
8.1
24
66
M13.9
ICD-10 Finland
Arthritis, unspecified
4.1
7.9
23
62
C03DA01
ATC
spironolactone; oral
3.2
7.8
36
133
L99
ICPC
Musculoskeletal disease other
9.6
7.7
15
17
C03CA01
ATC
furosemide; systemic
2.5
7.7
72
385
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
4.0
7.6
23
64
UJF32
NOMESCO Finland
Coloscopy
2.5
7.5
65
335
RT160, ,
NOMESCO Finland
83.6
7.5
8
*
L08.9
ICD-10 Finland
Local infection of skin and subcutaneous tissue, unspecified
9.4
7.2
14
16
E000001, ,
ATC
2.7
7.1
48
218
L98.4
ICD-10 Finland
Chronic ulcer of skin, not elsewhere classified
8.9
7.0
14
17
K74.3
ICD-10 Finland
Primary biliary cirrhosis
41.8
6.8
8
*
R13
ICD-10 Finland
Dysphagia
3.6
6.7
24
75
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.2
6.6
28
98
TND11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in joint, wrist or hand
15.1
6.5
10
7
RT271, ,
NOMESCO Finland
72.5
6.5
7
*
TNB11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in shoulder joint
72.5
6.5
7
*
C02DE02, ,
ATC
11.7
6.4
11
10
R4180
NOMESCO Finland
Podiatric therapy
11.7
6.4
11
10
M81.4
ICD-10 Finland
Drug-induced osteoporosis
27.8
6.3
8
*
XQ860
NOMESCO Finland
Laser Doppler measurement/scan of capillary perfusion
+∞
6.3
6
*
J01MA12
ATC
levofloxacin; systemic
2.6
6.2
45
210
J96.1
ICD-10 Finland
Chronic respiratory failure
9.1
6.2
12
14
NG1AE
NOMESCO Finland
Knee joint ultrasound exmination
13.2
6.2
10
8
M43.1
ICD-10 Finland
Spondylolisthesis
4.2
6.2
17
44
M43.0
ICD-10 Finland
Spondylolysis
10.6
6.1
11
11

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Rheumatology
66 [38004491]
3.0e+00
4.1e+00
—
1.0e+50
4.3e+00
4.7e+00
4.4e+00
cases:29.17%
controls:2.08%
cases:32.74%
controls:0.83%
—
—
cases:34.52%
controls:0.00%
cases:17.96%
controls:0.30%
cases:52.76%
controls:1.02%
cases:71.03%
controls:2.88%
49
35
119
1645
55
14
113
1666
—
58
0
110
1680
30
5
137
1674
86
17
77
1644
103
45
42
1517
Outpatient Visit
OP [9202]
1.0e+00
1.7e+00
1.8e+00
6.1e+00
1.8e+00
3.0e+00
3.0e+00
cases:78.57%
controls:57.14%
cases:78.57%
controls:39.70%
cases:36.31%
controls:8.99%
cases:66.07%
controls:0.42%
cases:39.52%
controls:10.07%
cases:93.25%
controls:41.42%
cases:97.93%
controls:70.68%
132
960
36
720
132
667
36
1013
61
151
107
1529
111
7
57
1673
66
169
101
1510
152
688
11
973
142
1104
3
458
nifedipine; oral, parenteral
C08CA05 [21601751]
4.0e+00
4.3e+00
—
—
—
4.2e+00
4.7e+00
cases:30.36%
controls:0.77%
cases:25.60%
controls:0.48%
—
—
—
—
—
—
cases:30.06%
controls:0.66%
cases:40.69%
controls:0.64%
51
13
117
1667
43
8
125
1672
—
—
—
49
11
114
1650
59
10
86
1552
hydroxychloroquine; oral
P01BA02 [21604889]
2.4e+00
3.1e+00
—
1.0e+50
3.1e+00
3.3e+00
3.5e+00
cases:14.29%
controls:1.55%
cases:17.26%
controls:0.95%
—
—
cases:3.57%
controls:0.00%
cases:5.99%
controls:0.30%
cases:24.54%
controls:1.14%
cases:32.41%
controls:1.41%
24
26
144
1654
29
16
139
1664
—
6
0
162
1680
10
5
157
1674
40
19
123
1642
47
22
98
1540
prednisolone; oral, parenteral
H02AB06 [21602734]
1.4e+00
2.1e+00
2.8e+00
—
3.3e+00
2.4e+00
1.9e+00
cases:27.38%
controls:8.87%
cases:25.00%
controls:3.81%
cases:9.52%
controls:0.65%
—
—
cases:11.98%
controls:0.48%
cases:36.20%
controls:4.94%
cases:44.83%
controls:10.95%
46
149
122
1531
42
64
126
1616
16
11
152
1669
—
20
8
147
1671
59
82
104
1579
65
171
80
1391
prednisolone
A07EA01 [21600653]
1.4e+00
2.1e+00
2.8e+00
—
3.3e+00
2.4e+00
1.9e+00
cases:27.38%
controls:8.87%
cases:25.00%
controls:3.81%
cases:9.52%
controls:0.65%
—
—
cases:11.98%
controls:0.48%
cases:36.20%
controls:4.94%
cases:44.83%
controls:11.08%
46
149
122
1531
42
64
126
1616
16
11
152
1669
—
20
8
147
1671
59
82
104
1579
65
173
80
1389
azathioprine; oral, parenteral
L04AX01 [21603927]
2.9e+00
3.0e+00
—
—
—
3.2e+00
3.3e+00
cases:5.95%
controls:0.36%
cases:6.55%
controls:0.36%
—
—
—
—
—
—
cases:9.82%
controls:0.42%
cases:14.48%
controls:0.64%
10
6
158
1674
11
6
157
1674
—
—
—
16
7
147
1654
21
10
124
1552
Pulmonary Disease
29 [38004472]
9.6e-01
1.9e+00
2.4e+00
—
2.9e+00
1.8e+00
1.7e+00
cases:13.69%
controls:5.71%
cases:16.67%
controls:3.04%
cases:6.55%
controls:0.65%
—
—
cases:5.39%
controls:0.30%
cases:17.18%
controls:3.25%
cases:28.97%
controls:6.79%
23
96
145
1584
28
51
140
1629
11
11
157
1669
—
9
5
158
1674
28
54
135
1607
42
106
103
1456
methotrexate
L01BA01 [21601423]
2.4e+00
2.7e+00
—
1.0e+50
—
3.1e+00
3.0e+00
cases:11.90%
controls:1.19%
cases:10.71%
controls:0.83%
—
—
cases:2.98%
controls:0.00%
—
—
cases:22.09%
controls:1.26%
cases:30.34%
controls:2.05%
20
20
148
1660
18
14
150
1666
—
5
0
163
1680
—
36
21
127
1640
44
32
101
1530
methotrexate; oral, parenteral
L04AX03 [21603929]
2.4e+00
2.7e+00
—
1.0e+50
—
3.1e+00
3.0e+00
cases:11.90%
controls:1.19%
cases:10.71%
controls:0.83%
—
—
cases:2.98%
controls:0.00%
—
—
cases:22.09%
controls:1.26%
cases:30.34%
controls:2.05%
20
20
148
1660
18
14
150
1666
—
5
0
163
1680
—
36
21
127
1640
44
32
101
1530
Office Visit
OMOP4822458 [581477]
1.1e+00
1.7e+00
2.3e+00
1.0e+50
2.6e+00
1.9e+00
1.4e+00
cases:19.64%
controls:7.68%
cases:14.88%
controls:2.98%
cases:3.57%
controls:0.36%
cases:2.98%
controls:0.00%
cases:5.39%
controls:0.42%
cases:18.40%
controls:3.31%
cases:28.97%
controls:9.35%
33
129
135
1551
25
50
143
1630
6
6
162
1674
5
0
163
1680
9
7
158
1672
30
55
133
1606
42
146
103
1416
Internal Medicine
11 [38004456]
1.2e+00
1.7e+00
1.9e+00
—
2.3e+00
2.1e+00
1.7e+00
cases:45.83%
controls:20.00%
cases:36.31%
controls:9.23%
cases:8.93%
controls:1.49%
—
—
cases:13.17%
controls:1.55%
cases:46.01%
controls:9.63%
cases:61.38%
controls:21.96%
77
336
91
1344
61
155
107
1525
15
25
153
1655
—
22
26
145
1653
75
160
88
1501
89
343
56
1219
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
7.4e-01
1.4e+00
3.2e+00
—
2.9e+00
1.8e+00
1.4e+00
cases:8.93%
controls:4.46%
cases:11.31%
controls:2.98%
cases:8.33%
controls:0.36%
—
—
cases:7.19%
controls:0.42%
cases:17.79%
controls:3.37%
cases:24.14%
controls:7.43%
15
75
153
1605
19
50
149
1630
14
6
154
1674
—
12
7
155
1672
29
56
134
1605
35
116
110
1446
Pharmacy visit
OMOP4822462 [581458]
1.1e+00
2.4e+00
9.4e-01
2.7e+00
1.2e+00
3.4e+00
1.0e+50
cases:98.21%
controls:94.76%
cases:98.21%
controls:82.92%
cases:63.69%
controls:40.71%
cases:16.67%
controls:1.37%
cases:70.06%
controls:40.32%
cases:99.39%
controls:83.74%
cases:100.00%
controls:95.13%
165
1592
3
88
165
1393
3
287
107
684
61
996
28
23
140
1657
117
677
50
1002
162
1391
1
270
145
1486
0
76
prednisone; oral
H02AB07 [21602735]
2.1e+00
2.7e+00
—
—
—
2.8e+00
2.3e+00
cases:9.52%
controls:1.25%
cases:5.95%
controls:0.42%
—
—
—
—
—
—
cases:7.98%
controls:0.54%
cases:11.72%
controls:1.34%
16
21
152
1659
10
7
158
1673
—
—
—
13
9
150
1652
17
21
128
1541
prednisone
A07EA03 [21600655]
2.1e+00
2.7e+00
—
—
—
2.8e+00
2.3e+00
cases:9.52%
controls:1.25%
cases:5.95%
controls:0.42%
—
—
—
—
—
—
cases:7.98%
controls:0.54%
cases:11.72%
controls:1.34%
16
21
152
1659
10
7
158
1673
—
—
—
13
9
150
1652
17
21
128
1541
FEV1
20150-9 [3024653]
2.4e+00
3.0e+00
—
—
—
—
4.1e+00
cases:7.74%
controls:0.77%
cases:8.93%
controls:0.48%
—
—
—
—
—
—
—
—
cases:16.55%
controls:0.32%
13
13
155
1667
15
8
153
1672
—
—
—
—
24
5
121
1557
FEV1/FVC
19926-5 [3011505]
2.4e+00
3.0e+00
—
—
—
—
4.1e+00
cases:7.74%
controls:0.77%
cases:8.93%
controls:0.48%
—
—
—
—
—
—
—
—
cases:16.55%
controls:0.32%
13
13
155
1667
15
8
153
1672
—
—
—
—
24
5
121
1557
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
2.4e+00
3.0e+00
—
—
—
—
4.1e+00
cases:7.74%
controls:0.77%
cases:8.93%
controls:0.48%
—
—
—
—
—
—
—
—
cases:16.55%
controls:0.32%
13
13
155
1667
15
8
153
1672
—
—
—
—
24
5
121
1557
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
9.6e-01
1.9e+00
3.2e+00
—
2.5e+00
1.9e+00
4.9e-01
cases:7.14%
controls:2.86%
cases:9.52%
controls:1.49%
cases:6.55%
controls:0.30%
—
—
cases:4.79%
controls:0.42%
cases:14.11%
controls:2.41%
cases:13.10%
controls:8.45%
12
48
156
1632
16
25
152
1655
11
5
157
1675
—
8
7
159
1672
23
40
140
1621
19
132
126
1430
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
9.2e-01
1.9e+00
3.2e+00
—
2.5e+00
1.9e+00
5.0e-01
cases:7.14%
controls:2.98%
cases:9.52%
controls:1.55%
cases:6.55%
controls:0.30%
—
—
cases:4.79%
controls:0.42%
cases:14.11%
controls:2.41%
cases:13.10%
controls:8.39%
12
50
156
1630
16
26
152
1654
11
5
157
1675
—
8
7
159
1672
23
40
140
1621
19
131
126
1431
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
1.0e+00
1.9e+00
3.2e+00
—
2.3e+00
1.8e+00
5.2e-01
cases:7.14%
controls:2.68%
cases:8.93%
controls:1.49%
cases:6.55%
controls:0.30%
—
—
cases:4.19%
controls:0.42%
cases:13.50%
controls:2.41%
cases:13.10%
controls:8.19%
12
45
156
1635
15
25
153
1655
11
5
157
1675
—
7
7
160
1672
22
40
141
1621
19
128
126
1434
Inpatient Hospital
21 [8717]
5.7e-01
1.4e+00
1.9e+00
—
2.9e+00
1.4e+00
8.4e-01
cases:46.43%
controls:32.80%
cases:32.14%
controls:10.54%
cases:7.74%
controls:1.19%
—
—
cases:12.57%
controls:0.77%
cases:31.90%
controls:10.72%
cases:51.03%
controls:30.99%
78
551
90
1129
54
177
114
1503
13
20
155
1660
—
21
13
146
1666
52
178
111
1483
74
484
71
1078
Monocytes [#/volume] in Blood
26484-6 [3001604]
7.8e-01
1.8e+00
—
—
3.2e+00
2.2e+00
1.7e+00
cases:7.14%
controls:3.39%
cases:12.50%
controls:2.38%
—
—
—
—
cases:6.59%
controls:0.30%
cases:18.40%
controls:2.41%
cases:24.14%
controls:5.51%
12
57
156
1623
21
40
147
1640
—
—
11
5
156
1674
30
40
133
1621
35
86
110
1476
Basophils [#/volume] in Blood
26444-0 [3006315]
7.8e-01
1.7e+00
—
—
3.2e+00
2.2e+00
1.7e+00
cases:7.14%
controls:3.39%
cases:12.50%
controls:2.44%
—
—
—
—
cases:6.59%
controls:0.30%
cases:18.40%
controls:2.41%
cases:24.14%
controls:5.57%
12
57
156
1623
21
41
147
1639
—
—
11
5
156
1674
30
40
133
1621
35
87
110
1475
Eosinophils [#/volume] in Blood
26449-9 [3013115]
7.7e-01
1.8e+00
—
—
3.2e+00
2.2e+00
1.6e+00
cases:7.74%
controls:3.75%
cases:13.10%
controls:2.44%
—
—
—
—
cases:6.59%
controls:0.30%
cases:19.02%
controls:2.53%
cases:24.14%
controls:6.08%
13
63
155
1617
22
41
146
1639
—
—
11
5
156
1674
31
42
132
1619
35
95
110
1467
Cardiology
6 [38004451]
7.7e-01
5.8e-01
2.3e+00
—
2.8e+00
1.9e+00
1.7e+00
cases:11.31%
controls:5.60%
cases:4.17%
controls:2.38%
cases:4.76%
controls:0.48%
—
—
cases:4.79%
controls:0.30%
cases:13.50%
controls:2.29%
cases:26.90%
controls:6.59%
19
94
149
1586
7
40
161
1640
8
8
160
1672
—
8
5
159
1674
22
38
141
1623
39
103
106
1459
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
8.5e-01
1.7e+00
—
—
3.2e+00
2.2e+00
1.6e+00
cases:7.74%
controls:3.45%
cases:12.50%
controls:2.56%
—
—
—
—
cases:6.59%
controls:0.30%
cases:18.40%
controls:2.53%
cases:23.45%
controls:5.63%
13
58
155
1622
21
43
147
1637
—
—
11
5
156
1674
30
42
133
1619
34
88
111
1474
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
1.6e+00
2.5e+00
—
—
—
2.9e+00
1.4e+00
cases:4.76%
controls:0.95%
cases:5.95%
controls:0.54%
—
—
—
—
—
—
cases:9.82%
controls:0.60%
cases:9.66%
controls:2.56%
8
16
160
1664
10
9
158
1671
—
—
—
16
10
147
1651
14
40
131
1522
lansoprazole; oral
A02BC03 [21600098]
1.0e+00
1.8e+00
—
—
2.4e+00
2.1e+00
9.5e-01
cases:13.10%
controls:5.12%
cases:12.50%
controls:2.26%
—
—
—
—
cases:5.39%
controls:0.54%
cases:13.50%
controls:1.87%
cases:13.79%
controls:5.83%
22
86
146
1594
21
38
147
1642
—
—
9
9
158
1670
22
31
141
1630
20
91
125
1471
Outpatient Hospital
22 [8756]
5.1e-01
1.2e+00
2.3e+00
—
2.6e+00
1.2e+00
8.6e-01
cases:36.31%
controls:25.48%
cases:21.43%
controls:7.68%
cases:5.36%
controls:0.54%
—
—
cases:7.19%
controls:0.60%
cases:22.70%
controls:7.77%
cases:42.76%
controls:23.94%
61
428
107
1252
36
129
132
1551
9
9
159
1671
—
12
10
155
1669
37
129
126
1532
62
374
83
1188
calcium (different salts in combination); oral
A12AA20 [21600872]
1.1e+00
1.3e+00
5.6e-01
—
2.3e+00
1.7e+00
1.8e+00
cases:19.64%
controls:7.62%
cases:18.45%
controls:6.07%
cases:2.98%
controls:1.73%
—
—
cases:8.38%
controls:0.89%
cases:28.22%
controls:6.56%
cases:43.45%
controls:11.27%
33
128
135
1552
31
102
137
1578
5
29
163
1651
—
14
15
153
1664
46
109
117
1552
63
176
82
1386
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
4.8e-01
1.6e+00
—
—
2.9e+00
2.1e+00
1.6e+00
cases:5.36%
controls:3.39%
cases:10.71%
controls:2.38%
—
—
—
—
cases:5.39%
controls:0.30%
cases:14.72%
controls:2.17%
cases:20.00%
controls:4.93%
9
57
159
1623
18
40
150
1640
—
—
9
5
158
1674
24
36
139
1625
29
77
116
1485
Monocytes/Leukocytes in Blood
26485-3 [3019069]
5.0e-01
1.6e+00
—
—
2.9e+00
2.1e+00
1.6e+00
cases:5.36%
controls:3.33%
cases:10.71%
controls:2.44%
—
—
—
—
cases:5.39%
controls:0.30%
cases:14.72%
controls:2.17%
cases:20.00%
controls:4.93%
9
56
159
1624
18
41
150
1639
—
—
9
5
158
1674
24
36
139
1625
29
77
116
1485
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
1.2e+00
2.6e+00
—
—
—
2.6e+00
1.8e+00
cases:17.26%
controls:6.07%
cases:20.83%
controls:1.96%
—
—
—
—
—
—
cases:20.86%
controls:1.93%
cases:29.66%
controls:6.72%
29
102
139
1578
35
33
133
1647
—
—
—
34
32
129
1629
43
105
102
1457
Basophils/Leukocytes in Blood
30180-4 [3022096]
4.8e-01
1.6e+00
—
—
2.9e+00
2.1e+00
1.5e+00
cases:5.36%
controls:3.39%
cases:10.71%
controls:2.38%
—
—
—
—
cases:5.39%
controls:0.30%
cases:14.72%
controls:2.17%
cases:19.31%
controls:4.99%
9
57
159
1623
18
40
150
1640
—
—
9
5
158
1674
24
36
139
1625
28
78
117
1484
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
5.1e-01
1.1e+00
2.7e+00
—
1.7e+00
1.6e+00
8.9e-01
cases:10.12%
controls:6.31%
cases:13.69%
controls:4.82%
cases:9.52%
controls:0.71%
—
—
cases:5.39%
controls:1.01%
cases:20.86%
controls:5.00%
cases:26.90%
controls:13.12%
17
106
151
1574
23
81
145
1599
16
12
152
1668
—
9
17
158
1662
34
83
129
1578
39
205
106
1357
Standard cardiac ultrasound examination
FM1AE [2001303278]
1.6e+00
1.9e+00
—
—
—
2.3e+00
2.1e+00
cases:6.55%
controls:1.37%
cases:4.17%
controls:0.65%
—
—
—
—
—
—
cases:5.52%
controls:0.60%
cases:13.10%
controls:1.79%
11
23
157
1657
7
11
161
1669
—
—
—
9
10
154
1651
19
28
126
1534
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
3.9e-01
1.4e+00
—
—
2.9e+00
1.9e+00
1.5e+00
cases:4.76%
controls:3.27%
cases:10.12%
controls:2.62%
—
—
—
—
cases:5.39%
controls:0.30%
cases:14.11%
controls:2.29%
cases:20.00%
controls:5.06%
8
55
160
1625
17
44
151
1636
—
—
9
5
158
1674
23
38
140
1623
29
79
116
1483
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
4.6e-01
1.5e+00
—
—
2.9e+00
1.9e+00
1.5e+00
cases:5.36%
controls:3.45%
cases:10.12%
controls:2.56%
—
—
—
—
cases:5.39%
controls:0.30%
cases:13.50%
controls:2.23%
cases:19.31%
controls:5.19%
9
58
159
1622
17
43
151
1637
—
—
9
5
158
1674
22
37
141
1624
28
81
117
1481
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
1.8e+00
3.6e+00
—
—
—
—
2.3e+00
cases:4.17%
controls:0.71%
cases:10.12%
controls:0.30%
—
—
—
—
—
—
—
—
cases:11.03%
controls:1.22%
7
12
161
1668
17
5
151
1675
—
—
—
—
16
19
129
1543
Gastroenterology
10 [38004455]
1.5e+00
2.1e+00
—
—
—
2.4e+00
1.8e+00
cases:10.12%
controls:2.56%
cases:10.71%
controls:1.49%
—
—
—
—
—
—
cases:12.27%
controls:1.26%
cases:22.07%
controls:4.55%
17
43
151
1637
18
25
150
1655
—
—
—
20
21
143
1640
32
71
113
1491
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
3.9e-01
1.6e+00
2.6e+00
—
1.9e+00
1.5e+00
5.8e-01
cases:8.33%
controls:5.77%
cases:12.50%
controls:2.80%
cases:5.95%
controls:0.48%
—
—
cases:4.79%
controls:0.77%
cases:12.88%
controls:3.31%
cases:18.62%
controls:11.33%
14
97
154
1583
21
47
147
1633
10
8
158
1672
—
8
13
159
1666
21
55
142
1606
27
177
118
1385
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.2e+00
1.8e+00
—
—
—
2.9e+00
1.6e+00
cases:10.12%
controls:3.15%
cases:5.95%
controls:1.07%
—
—
—
—
—
—
cases:10.43%
controls:0.66%
cases:17.24%
controls:3.91%
17
53
151
1627
10
18
158
1662
—
—
—
17
11
146
1650
25
61
120
1501
pantoprazole; oral, parenteral
A02BC02 [21600097]
5.0e-01
1.1e+00
1.5e+00
—
2.1e+00
1.6e+00
1.1e+00
cases:17.26%
controls:11.19%
cases:16.67%
controls:6.19%
cases:5.95%
controls:1.43%
—
—
cases:9.58%
controls:1.25%
cases:25.15%
controls:6.56%
cases:35.17%
controls:15.62%
29
188
139
1492
28
104
140
1576
10
24
158
1656
—
16
21
151
1658
41
109
122
1552
51
244
94
1318
pH of Urine
2756-5 [3015736]
1.1e+00
2.3e+00
—
—
2.7e+00
1.9e+00
2.3e-01
cases:5.95%
controls:2.14%
cases:8.33%
controls:0.89%
—
—
—
—
cases:4.19%
controls:0.30%
cases:11.04%
controls:1.75%
cases:8.28%
controls:6.66%
10
36
158
1644
14
15
154
1665
—
—
7
5
160
1674
18
29
145
1632
12
104
133
1458
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
9.8e-01
1.8e+00
2.9e+00
—
—
2.1e+00
5.6e-01
cases:6.55%
controls:2.56%
cases:6.55%
controls:1.19%
cases:5.36%
controls:0.30%
—
—
—
—
cases:12.27%
controls:1.63%
cases:11.72%
controls:7.04%
11
43
157
1637
11
20
157
1660
9
5
159
1675
—
—
20
27
143
1634
17
110
128
1452
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.8e-01
7.9e-01
2.6e+00
—
2.0e+00
1.2e+00
3.8e-01
cases:13.10%
controls:10.18%
cases:15.48%
controls:7.68%
cases:11.90%
controls:1.01%
—
—
cases:7.78%
controls:1.13%
cases:21.47%
controls:7.83%
cases:27.59%
controls:20.68%
22
171
146
1509
26
129
142
1551
20
17
148
1663
—
13
19
154
1660
35
130
128
1531
40
323
105
1239
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4.1e-01
1.5e+00
—
—
2.4e+00
1.8e+00
8.0e-01
cases:9.52%
controls:6.55%
cases:14.88%
controls:3.75%
—
—
—
—
cases:5.39%
controls:0.54%
cases:20.25%
controls:3.97%
cases:24.83%
controls:12.93%
16
110
152
1570
25
63
143
1617
—
—
9
9
158
1670
33
66
130
1595
36
202
109
1360
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
9.5e-01
2.5e+00
—
—
—
2.5e+00
1.4e+00
cases:4.76%
controls:1.90%
cases:7.14%
controls:0.60%
—
—
—
—
—
—
cases:8.59%
controls:0.78%
cases:12.41%
controls:3.27%
8
32
160
1648
12
10
156
1670
—
—
—
14
13
149
1648
18
51
127
1511
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
—
2.5e+00
—
—
—
2.4e+00
1.5e+00
—
—
cases:3.57%
controls:0.30%
—
—
—
—
—
—
cases:4.29%
controls:0.42%
cases:6.21%
controls:1.41%
—
6
5
162
1675
—
—
—
7
7
156
1654
9
22
136
1540
Physiotherapist
Z3226 [2001311560]
1.1e+00
2.6e+00
—
1.0e+50
—
2.4e+00
1.3e+00
cases:5.95%
controls:1.96%
cases:5.95%
controls:0.48%
—
—
cases:4.17%
controls:0.00%
—
—
cases:6.13%
controls:0.60%
cases:9.66%
controls:2.82%
10
33
158
1647
10
8
158
1672
—
7
0
161
1680
—
10
10
153
1651
14
44
131
1518
Connective tissue diseases, rheumatoid arthritis and comparable disease
202 [2001600200]
3.7e+00
—
—
—
1.0e+50
—
2.6e+00
cases:14.29%
controls:0.42%
—
—
—
—
—
—
cases:8.38%
controls:0.00%
—
—
cases:5.52%
controls:0.45%
24
7
144
1673
—
—
—
14
0
153
1679
—
8
7
137
1555
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
8.9e-01
1.5e+00
2.5e+00
—
—
1.1e+00
1.4e+00
cases:13.10%
controls:5.83%
cases:6.55%
controls:1.55%
cases:4.76%
controls:0.42%
—
—
—
—
cases:6.13%
controls:2.23%
cases:22.07%
controls:6.79%
22
98
146
1582
11
26
157
1654
8
7
160
1673
—
—
10
37
153
1624
32
106
113
1456
Thorax X-ray examination
GD1AA [2001303617]
1.1e+00
1.8e+00
—
1.0e+50
—
1.7e+00
1.5e+00
cases:13.10%
controls:4.58%
cases:11.31%
controls:1.96%
—
—
cases:4.76%
controls:0.00%
—
—
cases:12.88%
controls:2.71%
cases:24.14%
controls:6.40%
22
77
146
1603
19
33
149
1647
—
8
0
160
1680
—
21
45
142
1616
35
100
110
1462
omeprazole; oral, parenteral
A02BC01 [21600096]
1.4e+00
1.9e+00
—
—
—
1.7e+00
1.2e+00
cases:13.10%
controls:3.57%
cases:8.93%
controls:1.49%
—
—
—
—
—
—
cases:7.98%
controls:1.63%
cases:13.79%
controls:4.80%
22
60
146
1620
15
25
153
1655
—
—
—
13
27
150
1634
20
75
125
1487
Sicca syndrome [Sjögren]
M35.0 [45562711]
—
3.0e+00
—
—
1.0e+50
—
3.0e+00
—
—
cases:6.55%
controls:0.36%
—
—
—
—
cases:2.99%
controls:0.00%
—
—
cases:6.90%
controls:0.38%
—
11
6
157
1674
—
—
5
0
162
1679
—
10
6
135
1556
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
7.8e-01
1.9e+00
—
—
—
2.5e+00
1.5e+00
cases:3.57%
controls:1.67%
cases:5.95%
controls:0.89%
—
—
—
—
—
—
cases:9.82%
controls:0.90%
cases:15.17%
controls:3.97%
6
28
162
1652
10
15
158
1665
—
—
—
16
15
147
1646
22
62
123
1500
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
9.0e-01
1.7e+00
2.5e+00
—
1.7e+00
1.6e+00
8.6e-01
cases:5.95%
controls:2.50%
cases:7.74%
controls:1.55%
cases:3.57%
controls:0.30%
—
—
cases:2.99%
controls:0.54%
cases:9.20%
controls:1.99%
cases:13.79%
controls:6.34%
10
42
158
1638
13
26
155
1654
6
5
162
1675
—
5
9
162
1670
15
33
148
1628
20
99
125
1463
Physical Medicine And Rehabilitation
25 [38004468]
1.0e+00
1.5e+00
—
—
—
2.0e+00
1.0e+00
cases:11.90%
controls:4.58%
cases:8.93%
controls:2.08%
—
—
—
—
—
—
cases:11.04%
controls:1.69%
cases:17.93%
controls:7.36%
20
77
148
1603
15
35
153
1645
—
—
—
18
28
145
1633
26
115
119
1447
Emergency Room Visit
ER [9203]
7.1e-01
1.2e+00
1.7e+00
—
1.2e+00
8.7e-01
1.0e+00
cases:42.26%
controls:26.37%
cases:25.00%
controls:8.93%
cases:5.36%
controls:1.07%
—
—
cases:2.99%
controls:0.89%
cases:24.54%
controls:11.98%
cases:54.48%
controls:29.77%
71
443
97
1237
42
150
126
1530
9
18
159
1662
—
5
15
162
1664
40
199
123
1462
79
465
66
1097
Specific gravity of Urine by Refractometry
5810-7 [3019150]
1.5e+00
1.8e+00
—
—
—
2.1e+00
5.6e-01
cases:5.95%
controls:1.37%
cases:5.36%
controls:0.95%
—
—
—
—
—
—
cases:9.82%
controls:1.26%
cases:7.59%
controls:4.48%
10
23
158
1657
9
16
159
1664
—
—
—
16
21
147
1640
11
70
134
1492
FEV1/FVC --post bronchodilation
69970-2 [42868459]
2.5e+00
3.0e+00
—
—
—
—
—
cases:7.14%
controls:0.65%
cases:6.55%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
12
11
156
1669
11
6
157
1674
—
—
—
—
—
FEV1 --post bronchodilation
20155-8 [3023550]
2.5e+00
3.0e+00
—
—
—
—
—
cases:7.14%
controls:0.65%
cases:6.55%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
12
11
156
1669
11
6
157
1674
—
—
—
—
—
FEV1 percent change
69983-5 [42868472]
2.5e+00
3.0e+00
—
—
—
—
—
cases:7.14%
controls:0.65%
cases:6.55%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
12
11
156
1669
11
6
157
1674
—
—
—
—
—
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
2.5e+00
3.0e+00
—
—
—
—
—
cases:7.14%
controls:0.65%
cases:6.55%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
12
11
156
1669
11
6
157
1674
—
—
—
—
—
FVC percent change Respiratory system
69982-7 [42868471]
2.5e+00
3.0e+00
—
—
—
—
—
cases:7.14%
controls:0.65%
cases:6.55%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
12
11
156
1669
11
6
157
1674
—
—
—
—
—
Medical doctor
Z2221 [2001311556]
1.1e+00
1.7e+00
—
1.0e+50
—
2.2e+00
1.4e+00
cases:7.74%
controls:2.80%
cases:7.14%
controls:1.37%
—
—
cases:3.57%
controls:0.00%
—
—
cases:11.66%
controls:1.38%
cases:15.17%
controls:4.16%
13
47
155
1633
12
23
156
1657
—
6
0
162
1680
—
19
23
144
1638
22
65
123
1497
Arthrocentesis, unspecified region, unspecified region
TNX10 [2001308560]
2.3e+00
—
—
—
—
—
2.9e+00
cases:4.76%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
cases:8.97%
controls:0.51%
8
8
160
1672
—
—
—
—
—
13
8
132
1554
Differential panel, method unspecified - Blood
69738-3 [42870588]
9.2e-01
1.8e+00
—
—
—
1.9e+00
1.5e+00
cases:5.36%
controls:2.20%
cases:8.93%
controls:1.55%
—
—
—
—
—
—
cases:11.04%
controls:1.75%
cases:12.41%
controls:3.20%
9
37
159
1643
15
26
153
1654
—
—
—
18
29
145
1632
18
50
127
1512
Other specified special examinations
Z01.8 [45581003]
1.5e+00
1.6e+00
—
—
—
2.1e+00
1.3e+00
cases:6.55%
controls:1.61%
cases:4.76%
controls:0.95%
—
—
—
—
—
—
cases:7.98%
controls:1.02%
cases:6.90%
controls:1.92%
11
27
157
1653
8
16
160
1664
—
—
—
13
17
150
1644
10
30
135
1532
Physiotherapy
R4110 [2001310233]
6.8e-01
2.1e+00
—
1.0e+50
—
1.7e+00
1.1e+00
cases:5.95%
controls:3.10%
cases:6.55%
controls:0.83%
—
—
cases:3.57%
controls:0.00%
—
—
cases:5.52%
controls:1.08%
cases:10.34%
controls:3.59%
10
52
158
1628
11
14
157
1666
—
6
0
162
1680
—
9
18
154
1643
15
56
130
1506
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
3.1e-01
6.1e-01
2.3e+00
—
1.8e+00
7.4e-01
3.2e-01
cases:14.88%
controls:11.37%
cases:16.67%
controls:9.82%
cases:11.90%
controls:1.37%
—
—
cases:10.78%
controls:2.03%
cases:21.47%
controls:11.56%
cases:31.03%
controls:24.65%
25
191
143
1489
28
165
140
1515
20
23
148
1657
—
18
34
149
1645
35
192
128
1469
45
385
100
1177
alendronic acid; oral
M05BA04 [21604152]
1.2e+00
1.7e+00
—
—
—
2.3e+00
2.4e+00
cases:3.57%
controls:1.13%
cases:2.98%
controls:0.54%
—
—
—
—
—
—
cases:5.52%
controls:0.60%
cases:10.34%
controls:1.02%
6
19
162
1661
5
9
163
1671
—
—
—
9
10
154
1651
15
16
130
1546
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
1.1e+00
2.9e+00
1.0e+50
—
—
1.7e+00
1.7e-02
cases:3.57%
controls:1.19%
cases:5.95%
controls:0.36%
cases:3.57%
controls:0.00%
—
—
—
—
cases:5.52%
controls:1.08%
cases:3.45%
controls:3.39%
6
20
162
1660
10
6
158
1674
6
0
162
1680
—
—
9
18
154
1643
5
53
140
1509
Normoblasts [#/volume] in Blood
715-3 [3021589]
-9.8e-02
9.3e-01
1.9e+00
—
2.0e+00
1.2e+00
1.3e+00
cases:2.98%
controls:3.27%
cases:5.95%
controls:2.44%
cases:3.57%
controls:0.54%
—
—
cases:3.59%
controls:0.48%
cases:7.98%
controls:2.53%
cases:14.48%
controls:4.55%
5
55
163
1625
10
41
158
1639
6
9
162
1671
—
6
8
161
1671
13
42
150
1619
21
71
124
1491
Hand and fingers X-ray examination
ND2AA [2001307607]
2.1e+00
—
—
—
—
—
2.4e+00
cases:4.17%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:6.21%
controls:0.58%
7
9
161
1671
—
—
—
—
—
9
9
136
1553
Case Management Agency
251B00000X [38004193]
3.1e-01
4.1e-01
9.1e-01
2.6e+00
9.1e-01
5.5e-01
4.4e-01
cases:43.45%
controls:36.07%
cases:37.50%
controls:28.57%
cases:23.81%
controls:11.19%
cases:10.71%
controls:0.89%
cases:22.75%
controls:10.60%
cases:47.85%
controls:34.62%
cases:65.52%
controls:54.99%
73
606
95
1074
63
480
105
1200
40
188
128
1492
18
15
150
1665
38
178
129
1501
78
575
85
1086
95
859
50
703
Anaemia, unspecified
D64.9 [45600610]
—
2.7e+00
—
—
—
1.8e+00
1.7e+00
—
—
cases:4.17%
controls:0.30%
—
—
—
—
—
—
cases:3.07%
controls:0.54%
cases:5.52%
controls:1.09%
—
7
5
161
1675
—
—
—
5
9
158
1652
8
17
137
1545
Intravenous
ZX120 [2001311495]
1.9e+00
—
—
—
—
2.4e+00
1.9e+00
cases:2.98%
controls:0.48%
—
—
—
—
—
—
—
—
cases:4.29%
controls:0.42%
cases:6.90%
controls:1.09%
5
8
163
1672
—
—
—
—
7
7
156
1654
10
17
135
1545
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
5.9e-01
2.0e+00
—
—
—
2.2e+00
3.9e-01
cases:2.98%
controls:1.67%
cases:4.76%
controls:0.65%
—
—
—
—
—
—
cases:7.98%
controls:0.96%
cases:6.21%
controls:4.29%
5
28
163
1652
8
11
160
1669
—
—
—
13
16
150
1645
9
67
136
1495
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
—
2.1e+00
—
—
—
2.2e+00
1.7e+00
—
—
cases:2.98%
controls:0.36%
—
—
—
—
—
—
cases:3.68%
controls:0.42%
cases:6.90%
controls:1.28%
—
5
6
163
1674
—
—
—
6
7
157
1654
10
20
135
1542
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
7.9e-01
1.9e+00
—
—
—
2.1e+00
7.6e-01
cases:2.98%
controls:1.37%
cases:4.76%
controls:0.77%
—
—
—
—
—
—
cases:5.52%
controls:0.72%
cases:4.83%
controls:2.30%
5
23
163
1657
8
13
160
1667
—
—
—
9
12
154
1649
7
36
138
1526
sildenafil; oral
G04BE03 [21602648]
—
—
—
—
—
2.1e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:4.29%
controls:0.54%
cases:6.21%
controls:1.15%
—
—
—
—
—
7
9
156
1652
9
18
136
1544
Supplier / Service Provider
OMOP5117446 [33004]
-8.2e-01
5.2e-01
2.3e+00
—
—
—
4.6e+00
cases:13.10%
controls:25.54%
cases:10.71%
controls:6.67%
cases:2.98%
controls:0.30%
—
—
—
—
—
—
cases:24.14%
controls:0.32%
22
429
146
1251
18
112
150
1568
5
5
163
1675
—
—
—
35
5
110
1557
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
1.3e+00
1.7e+00
—
—
—
2.0e+00
1.7e+00
cases:4.76%
controls:1.31%
cases:3.57%
controls:0.65%
—
—
—
—
—
—
cases:4.91%
controls:0.66%
cases:12.41%
controls:2.50%
8
22
160
1658
6
11
162
1669
—
—
—
8
11
155
1650
18
39
127
1523
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
4.4e-01
4.7e-01
2.2e+00
—
1.5e+00
5.6e-01
2.3e-01
cases:14.29%
controls:9.70%
cases:13.10%
controls:8.63%
cases:10.12%
controls:1.25%
—
—
cases:7.78%
controls:1.91%
cases:15.95%
controls:9.81%
cases:23.45%
controls:19.59%
24
163
144
1517
22
145
146
1535
17
21
151
1659
—
13
32
154
1647
26
163
137
1498
34
306
111
1256
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
4.8e-02
4.7e-01
2.0e+00
—
1.6e+00
7.7e-01
5.4e-01
cases:8.33%
controls:7.98%
cases:10.71%
controls:6.96%
cases:10.12%
controls:1.49%
—
—
cases:7.78%
controls:1.61%
cases:15.34%
controls:7.71%
cases:24.14%
controls:15.62%
14
134
154
1546
18
117
150
1563
17
25
151
1655
—
13
27
154
1652
25
128
138
1533
35
244
110
1318
cefalexin; oral
J01DB01 [21602870]
7.3e-01
9.9e-01
—
—
1.4e+00
9.6e-01
8.9e-01
cases:41.07%
controls:25.06%
cases:20.83%
controls:8.93%
—
—
—
—
cases:3.59%
controls:0.95%
cases:19.02%
controls:8.25%
cases:47.59%
controls:27.08%
69
421
99
1259
35
150
133
1530
—
—
6
16
161
1663
31
137
132
1524
69
423
76
1139
furosemide; oral, parenteral
C03CA01 [21601518]
5.3e-01
1.2e+00
—
—
9.9e-01
1.2e+00
1.1e+00
cases:7.74%
controls:4.70%
cases:10.71%
controls:3.51%
—
—
—
—
cases:2.99%
controls:1.13%
cases:12.27%
controls:3.91%
cases:15.17%
controls:5.70%
13
79
155
1601
18
59
150
1621
—
—
5
19
162
1660
20
65
143
1596
22
89
123
1473
pH of Serum or Plasma
2753-2 [3018418]
8.6e-01
1.7e+00
—
—
—
1.7e+00
9.1e-01
cases:3.57%
controls:1.55%
cases:4.76%
controls:0.89%
—
—
—
—
—
—
cases:4.91%
controls:0.96%
cases:7.59%
controls:3.20%
6
26
162
1654
8
15
160
1665
—
—
—
8
16
155
1645
11
50
134
1512
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
5.3e-01
1.2e+00
—
—
—
2.4e+00
9.7e-01
cases:3.57%
controls:2.14%
cases:4.17%
controls:1.31%
—
—
—
—
—
—
cases:9.82%
controls:1.02%
cases:12.41%
controls:5.12%
6
36
162
1644
7
22
161
1658
—
—
—
16
17
147
1644
18
80
127
1482
12 lead EKG panel
34534-8 [3044889]
5.5e-01
1.1e+00
2.2e+00
—
—
7.7e-01
6.2e-01
cases:10.12%
controls:6.07%
cases:9.52%
controls:3.51%
cases:5.36%
controls:0.60%
—
—
—
—
cases:7.98%
controls:3.85%
cases:18.62%
controls:10.95%
17
102
151
1578
16
59
152
1621
9
10
159
1670
—
—
13
64
150
1597
27
171
118
1391
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
1.7e-01
4.7e-01
1.9e+00
—
1.3e+00
6.1e-01
2.3e-01
cases:14.29%
controls:12.38%
cases:17.26%
controls:11.49%
cases:12.50%
controls:2.02%
—
—
cases:8.98%
controls:2.68%
cases:22.09%
controls:13.31%
cases:29.66%
controls:25.03%
24
208
144
1472
29
193
139
1487
21
34
147
1646
—
15
45
152
1634
36
221
127
1440
43
391
102
1171
Leukocytes [#/volume] in Blood
26464-8 [3010813]
2.3e-01
3.6e-01
1.8e+00
—
1.4e+00
5.5e-01
2.4e-01
cases:16.07%
controls:13.21%
cases:17.26%
controls:12.68%
cases:13.10%
controls:2.38%
—
—
cases:11.38%
controls:3.22%
cases:22.09%
controls:14.09%
cases:31.72%
controls:26.70%
27
222
141
1458
29
213
139
1467
22
40
146
1640
—
19
54
148
1625
36
234
127
1427
46
417
99
1145
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
2.2e-01
3.7e-01
1.8e+00
—
1.4e+00
5.5e-01
2.5e-01
cases:16.07%
controls:13.27%
cases:17.26%
controls:12.62%
cases:13.10%
controls:2.38%
—
—
cases:11.38%
controls:3.22%
cases:22.09%
controls:14.09%
cases:31.72%
controls:26.63%
27
223
141
1457
29
212
139
1468
22
40
146
1640
—
19
54
148
1625
36
234
127
1427
46
416
99
1146
Platelets [#/volume] in Blood
26515-7 [3007461]
2.3e-01
3.7e-01
1.8e+00
—
1.4e+00
5.5e-01
2.5e-01
cases:16.07%
controls:13.21%
cases:17.26%
controls:12.62%
cases:13.10%
controls:2.38%
—
—
cases:11.38%
controls:3.22%
cases:22.09%
controls:14.09%
cases:31.72%
controls:26.63%
27
222
141
1458
29
212
139
1468
22
40
146
1640
—
19
54
148
1625
36
234
127
1427
46
416
99
1146
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
2.2e-01
3.7e-01
1.8e+00
—
1.4e+00
5.5e-01
2.5e-01
cases:16.07%
controls:13.27%
cases:17.26%
controls:12.62%
cases:13.10%
controls:2.38%
—
—
cases:11.38%
controls:3.22%
cases:22.09%
controls:14.09%
cases:31.72%
controls:26.63%
27
223
141
1457
29
212
139
1468
22
40
146
1640
—
19
54
148
1625
36
234
127
1427
46
416
99
1146
MCH [Entitic mass]
28539-5 [3035941]
2.2e-01
3.7e-01
1.8e+00
—
1.4e+00
5.5e-01
2.5e-01
cases:16.07%
controls:13.27%
cases:17.26%
controls:12.62%
cases:13.10%
controls:2.38%
—
—
cases:11.38%
controls:3.22%
cases:22.09%
controls:14.03%
cases:31.72%
controls:26.57%
27
223
141
1457
29
212
139
1468
22
40
146
1640
—
19
54
148
1625
36
233
127
1428
46
415
99
1147
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
2.2e-01
3.7e-01
1.8e+00
—
1.4e+00
5.5e-01
2.5e-01
cases:16.07%
controls:13.27%
cases:17.26%
controls:12.62%
cases:13.10%
controls:2.38%
—
—
cases:11.38%
controls:3.22%
cases:22.09%
controls:14.03%
cases:31.72%
controls:26.57%
27
223
141
1457
29
212
139
1468
22
40
146
1640
—
19
54
148
1625
36
233
127
1428
46
415
99
1147
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
2.2e-01
3.7e-01
1.8e+00
—
1.3e+00
5.3e-01
2.4e-01
cases:16.07%
controls:13.27%
cases:17.26%
controls:12.62%
cases:13.10%
controls:2.38%
—
—
cases:11.38%
controls:3.28%
cases:22.09%
controls:14.27%
cases:31.72%
controls:26.70%
27
223
141
1457
29
212
139
1468
22
40
146
1640
—
19
55
148
1624
36
237
127
1424
46
417
99
1145
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
—
—
—
—
—
—
3.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.28%
controls:0.38%
—
—
—
—
—
—
12
6
133
1556
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
6.0e-01
1.6e+00
—
—
—
1.4e+00
6.3e-01
cases:4.76%
controls:2.68%
cases:7.14%
controls:1.49%
—
—
—
—
—
—
cases:6.75%
controls:1.69%
cases:9.66%
controls:5.38%
8
45
160
1635
12
25
156
1655
—
—
—
11
28
152
1633
14
84
131
1478
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
—
—
—
—
—
—
3.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.66%
controls:0.51%
—
—
—
—
—
—
14
8
131
1554
Dyspnoea
R06.0 [45558449]
7.7e-01
1.6e+00
—
—
—
1.9e+00
1.2e+00
cases:4.17%
controls:1.96%
cases:3.57%
controls:0.71%
—
—
—
—
—
—
cases:4.91%
controls:0.78%
cases:11.03%
controls:3.78%
7
33
161
1647
6
12
162
1668
—
—
—
8
13
155
1648
16
59
129
1503
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
6.9e-01
1.6e+00
—
—
—
1.4e+00
7.3e-01
cases:6.55%
controls:3.39%
cases:7.74%
controls:1.73%
—
—
—
—
—
—
cases:7.36%
controls:1.93%
cases:12.41%
controls:6.40%
11
57
157
1623
13
29
155
1651
—
—
—
12
32
151
1629
18
100
127
1462
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.34%
controls:0.64%
—
—
—
—
—
—
15
10
130
1552
Neurology
13 [38004458]
9.0e-01
9.3e-01
—
—
-1.0e+50
1.1e+00
7.6e-01
cases:16.07%
controls:7.20%
cases:8.33%
controls:3.45%
—
—
—
—
cases:0.00%
controls:0.48%
cases:10.43%
controls:3.67%
cases:19.31%
controls:10.05%
27
121
141
1559
14
58
154
1622
—
—
0
8
167
1671
17
61
146
1600
28
157
117
1405
Extractable nuclear Ab [Units/volume] in Serum
30342-0 [3015171]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:0.32%
—
—
—
—
—
—
7
5
138
1557
General Surgery
2 [38004447]
8.0e-01
1.1e+00
—
—
1.0e+00
7.6e-01
8.0e-01
cases:35.12%
controls:19.52%
cases:18.45%
controls:6.79%
—
—
—
—
cases:2.99%
controls:1.07%
cases:14.11%
controls:7.10%
cases:33.10%
controls:18.25%
59
328
109
1352
31
114
137
1566
—
—
5
18
162
1661
23
118
140
1543
48
285
97
1277
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:0.38%
—
—
—
—
—
—
8
6
137
1556
Care involving use of other rehabilitation procedures
Z50.8 [45556842]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.32%
—
—
—
—
—
—
6
5
139
1557
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
8.8e-01
1.3e+00
—
—
—
1.7e+00
9.4e-01
cases:5.95%
controls:2.56%
cases:6.55%
controls:1.96%
—
—
—
—
—
—
cases:7.98%
controls:1.63%
cases:14.48%
controls:6.21%
10
43
158
1637
11
33
157
1647
—
—
—
13
27
150
1634
21
97
124
1465
Coloscopy
UJF32 [2001305029]
0.0e+00
1.5e+00
—
—
—
1.5e+00
1.1e+00
cases:2.98%
controls:2.98%
cases:5.36%
controls:1.25%
—
—
—
—
—
—
cases:3.68%
controls:0.84%
cases:10.34%
controls:3.84%
5
50
163
1630
9
21
159
1659
—
—
—
6
14
157
1647
15
60
130
1502
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
—
2.5e+00
—
—
—
—
—
—
—
cases:3.57%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
6
5
162
1675
—
—
—
—
—
etoricoxib; oral
M01AH05 [21603996]
4.5e-01
7.5e-01
2.5e+00
—
—
-4.7e-02
-4.6e-02
cases:12.50%
controls:8.33%
cases:7.14%
controls:3.51%
cases:3.57%
controls:0.30%
—
—
—
—
cases:3.68%
controls:3.85%
cases:13.10%
controls:13.64%
21
140
147
1540
12
59
156
1621
6
5
162
1675
—
—
6
64
157
1597
19
213
126
1349
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
—
—
—
—
—
2.5e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:4.29%
controls:0.36%
cases:6.21%
controls:2.18%
—
—
—
—
—
7
6
156
1655
9
34
136
1528
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
—
1.6e+00
—
—
—
2.5e+00
1.1e+00
—
—
cases:4.17%
controls:0.89%
—
—
—
—
—
—
cases:4.91%
controls:0.42%
cases:8.97%
controls:3.33%
—
7
15
161
1665
—
—
—
8
7
155
1654
13
52
132
1510
sucralfate; oral
A02BX02 [21600111]
2.5e+00
—
—
—
—
—
—
cases:4.17%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
7
6
161
1674
—
—
—
—
—
—
High resolution CT examination of lungs
GD1DD [2001303632]
—
—
—
1.0e+50
—
—
2.4e+00
—
—
—
—
—
—
cases:2.98%
controls:0.00%
—
—
—
—
cases:6.21%
controls:0.58%
—
—
—
5
0
163
1680
—
—
9
9
136
1553
Laboratory Visit
OMOP4822461 [32036]
1.9e-01
2.1e-01
1.3e+00
—
1.1e+00
3.6e-01
1.6e-01
cases:16.67%
controls:14.23%
cases:18.45%
controls:15.54%
cases:14.88%
controls:4.40%
—
—
cases:13.17%
controls:4.82%
cases:22.70%
controls:17.04%
cases:33.79%
controls:30.35%
28
239
140
1441
31
261
137
1419
25
74
143
1606
—
22
81
145
1598
37
283
126
1378
49
474
96
1088
Rheumatoid/seropositive arthritis
L88 [2002000707]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.38%
—
—
—
—
—
—
6
6
139
1556
Gastro-oesophageal reflux disease with oesophagitis
K21.0 [45543296]
1.7e+00
2.3e+00
—
—
—
—
1.5e+00
cases:2.98%
controls:0.54%
cases:5.36%
controls:0.54%
—
—
—
—
—
—
—
—
cases:4.83%
controls:1.09%
5
9
163
1671
9
9
159
1671
—
—
—
—
7
17
138
1545
Arthritis, unspecified
M13.9 [45567463]
2.3e+00
—
—
—
—
—
—
cases:4.76%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
8
8
160
1672
—
—
—
—
—
—
Pneumonia, unspecified
J18.9 [45601123]
3.9e-01
2.3e+00
—
—
—
—
9.1e-01
cases:3.57%
controls:2.44%
cases:4.17%
controls:0.42%
—
—
—
—
—
—
—
—
cases:7.59%
controls:3.20%
6
41
162
1639
7
7
161
1673
—
—
—
—
11
50
134
1512
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
7.9e-01
2.3e+00
—
—
—
—
—
cases:2.98%
controls:1.37%
cases:3.57%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
5
23
163
1657
6
6
162
1674
—
—
—
—
—
Dysphagia
R13 [45573013]
2.3e+00
—
—
—
—
—
—
cases:3.57%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
6
6
162
1674
—
—
—
—
—
—
cisapride; oral, rectal
A03FA02 [21600485]
2.3e+00
—
—
—
—
—
—
cases:5.95%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
10
11
158
1669
—
—
—
—
—
—
esomeprazole; oral, parenteral
A02BC05 [21600100]
4.5e-01
7.4e-01
1.3e+00
—
—
1.2e+00
1.1e+00
cases:10.71%
controls:7.08%
cases:8.33%
controls:4.17%
cases:3.57%
controls:1.01%
—
—
—
—
cases:12.88%
controls:4.46%
cases:22.07%
controls:8.58%
18
119
150
1561
14
70
154
1610
6
17
162
1663
—
—
21
74
142
1587
32
134
113
1428
risedronic acid; oral
M05BA07 [21604155]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.45%
—
—
—
—
—
—
6
7
139
1555
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.45%
—
—
—
—
—
—
6
7
139
1555
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
4.3e-01
—
—
—
—
2.2e+00
5.5e-01
cases:2.98%
controls:1.96%
—
—
—
—
—
—
—
—
cases:4.29%
controls:0.48%
cases:5.52%
controls:3.27%
5
33
163
1647
—
—
—
—
7
8
156
1653
8
51
137
1511
nystatin; oral
A07AA02 [21600604]
2.2e+00
—
—
—
—
—
—
cases:3.57%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
162
1673
—
—
—
—
—
—
General Practice
1 [38004446]
5.6e-01
1.1e+00
2.3e+00
—
—
1.0e+00
6.1e-01
cases:12.50%
controls:7.56%
cases:8.93%
controls:3.10%
cases:2.98%
controls:0.30%
—
—
—
—
cases:9.82%
controls:3.67%
cases:20.00%
controls:11.91%
21
127
147
1553
15
52
153
1628
5
5
163
1675
—
—
16
61
147
1600
29
186
116
1376
CBC panel - Blood by Automated count
58410-2 [40761511]
1.0e-01
5.9e-01
1.4e+00
—
8.0e-01
7.6e-01
2.5e-01
cases:11.90%
controls:10.89%
cases:14.29%
controls:8.45%
cases:5.95%
controls:1.55%
—
—
cases:4.79%
controls:2.20%
cases:17.79%
controls:9.21%
cases:26.21%
controls:21.64%
20
183
148
1497
24
142
144
1538
10
26
158
1654
—
8
37
159
1642
29
153
134
1508
38
338
107
1224
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.21%
controls:0.77%
—
—
—
—
—
—
9
12
136
1550
diltiazem; oral
C08DB01 [21601771]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.21%
controls:0.77%
—
—
—
—
—
—
9
12
136
1550
Rhinopharyngoscopy
UDH02 [2001301680]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.51%
—
—
—
—
—
—
6
8
139
1554
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
—
—
—
—
—
2.1e+00
8.1e-01
—
—
—
—
—
—
—
—
—
—
cases:4.29%
controls:0.54%
cases:6.90%
controls:3.20%
—
—
—
—
—
7
9
156
1652
10
50
135
1512
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.90%
controls:0.90%
—
—
—
—
—
—
10
14
135
1548
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.21%
controls:0.83%
—
—
—
—
—
—
9
13
136
1549
Iron deficiency anaemia, unspecified
D50.9 [45605373]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:0.64%
—
—
—
—
—
—
7
10
138
1552
Infectious Disease
44 [38004484]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.28%
controls:1.22%
—
—
—
—
—
—
12
19
133
1543
Spinal stenosis
M48.0 [45557888]
—
2.0e+00
—
—
—
—
—
—
—
cases:4.17%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
7
10
161
1670
—
—
—
—
—
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:0.70%
—
—
—
—
—
—
7
11
138
1551
Foot and toes X-ray examination
NH3AA [2001308267]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:0.70%
—
—
—
—
—
—
7
11
138
1551
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
1.9e-01
—
—
—
—
1.9e+00
7.9e-01
cases:3.57%
controls:2.98%
—
—
—
—
—
—
—
—
cases:5.52%
controls:0.84%
cases:9.66%
controls:4.61%
6
50
162
1630
—
—
—
—
9
14
154
1647
14
72
131
1490
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
9.8e-01
1.1e+00
—
—
—
1.9e+00
7.6e-01
cases:4.17%
controls:1.61%
cases:3.57%
controls:1.19%
—
—
—
—
—
—
cases:7.98%
controls:1.26%
cases:10.34%
controls:5.12%
7
27
161
1653
6
20
162
1660
—
—
—
13
21
150
1640
15
80
130
1482
Stomach Pathology biopsy report
66114-0 [40768797]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:0.77%
—
—
—
—
—
—
7
12
138
1550
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
—
7.9e-01
—
—
—
1.8e+00
7.9e-01
—
—
cases:2.98%
controls:1.37%
—
—
—
—
—
—
cases:6.13%
controls:1.02%
cases:8.97%
controls:4.29%
—
5
23
163
1657
—
—
—
10
17
153
1644
13
67
132
1495
Essential (primary) hypertension
I10 [45591453]
4.2e-01
6.3e-01
1.5e+00
—
1.8e+00
4.3e-01
1.0e-01
cases:16.67%
controls:11.61%
cases:8.93%
controls:4.94%
cases:3.57%
controls:0.83%
—
—
cases:4.19%
controls:0.71%
cases:9.82%
controls:6.62%
cases:19.31%
controls:17.73%
28
195
140
1485
15
83
153
1597
6
14
162
1666
—
7
12
160
1667
16
110
147
1551
28
277
117
1285
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
7.7e-01
1.7e+00
—
—
—
1.8e+00
6.2e-01
cases:4.17%
controls:1.96%
cases:3.57%
controls:0.65%
—
—
—
—
—
—
cases:4.91%
controls:0.84%
cases:6.90%
controls:3.84%
7
33
161
1647
6
11
162
1669
—
—
—
8
14
155
1647
10
60
135
1502
Spirometry study
18759-1 [3000492]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:0.96%
—
—
—
—
—
—
8
15
137
1547
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
—
—
—
—
—
1.7e+00
9.6e-01
—
—
—
—
—
—
—
—
—
—
cases:4.91%
controls:0.90%
cases:8.97%
controls:3.65%
—
—
—
—
—
8
15
155
1646
13
57
132
1505
Leukocytes [#/volume] in Urine
30405-5 [3018095]
4.0e-01
9.4e-01
—
—
—
1.7e+00
5.9e-01
cases:2.98%
controls:2.02%
cases:3.57%
controls:1.43%
—
—
—
—
—
—
cases:6.75%
controls:1.26%
cases:8.97%
controls:5.19%
5
34
163
1646
6
24
162
1656
—
—
—
11
21
152
1640
13
81
132
1481
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
1.5e+00
1.7e+00
—
—
—
1.7e+00
6.2e-01
cases:4.17%
controls:0.95%
cases:4.17%
controls:0.77%
—
—
—
—
—
—
cases:6.13%
controls:1.14%
cases:6.90%
controls:3.84%
7
16
161
1664
7
13
161
1667
—
—
—
10
19
153
1642
10
60
135
1502
hydrochlorothiazide; oral
C03AA03 [21601466]
7.5e-01
1.7e+00
—
—
—
—
3.1e-01
cases:3.57%
controls:1.73%
cases:5.36%
controls:1.01%
—
—
—
—
—
—
—
—
cases:4.14%
controls:3.07%
6
29
162
1651
9
17
159
1663
—
—
—
—
6
48
139
1514
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2.1e-01
1.4e+00
—
—
—
1.7e+00
7.6e-01
cases:3.57%
controls:2.92%
cases:5.95%
controls:1.61%
—
—
—
—
—
—
cases:7.36%
controls:1.44%
cases:9.66%
controls:4.74%
6
49
162
1631
10
27
158
1653
—
—
—
12
24
151
1637
14
74
131
1488
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.21%
controls:1.22%
—
—
—
—
—
—
9
19
136
1543
Bacteria [Presence] in Urine
87829-8 [36304419]
—
—
—
—
—
1.7e+00
8.9e-01
—
—
—
—
—
—
—
—
—
—
cases:4.91%
controls:0.96%
cases:7.59%
controls:3.27%
—
—
—
—
—
8
16
155
1645
11
51
134
1511
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
-4.8e-01
2.9e-01
1.7e+00
—
8.1e-01
4.1e-01
4.3e-01
cases:5.36%
controls:8.39%
cases:10.12%
controls:7.80%
cases:6.55%
controls:1.31%
—
—
cases:4.19%
controls:1.91%
cases:12.27%
controls:8.49%
cases:22.07%
controls:15.62%
9
141
159
1539
17
131
151
1549
11
22
157
1658
—
7
32
160
1647
20
141
143
1520
32
244
113
1318
Other and unspecified abdominal pain
R10.4 [45568113]
8.7e-01
1.7e+00
—
—
—
—
2.3e-01
cases:9.52%
controls:4.23%
cases:5.95%
controls:1.19%
—
—
—
—
—
—
—
—
cases:6.21%
controls:4.99%
16
71
152
1609
10
20
158
1660
—
—
—
—
9
78
136
1484
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
—
1.7e+00
1.0e+50
—
—
1.6e+00
9.7e-01
—
—
cases:2.98%
controls:0.54%
cases:2.98%
controls:0.00%
—
—
—
—
cases:4.91%
controls:1.02%
cases:8.97%
controls:3.59%
—
5
9
163
1671
5
0
163
1680
—
—
8
17
155
1644
13
56
132
1506
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
1.8e-01
4.5e-01
1.6e+00
—
7.2e-01
5.3e-01
9.4e-02
cases:13.69%
controls:11.67%
cases:14.88%
controls:10.06%
cases:7.74%
controls:1.73%
—
—
cases:4.79%
controls:2.38%
cases:18.40%
controls:11.68%
cases:24.83%
controls:23.11%
23
196
145
1484
25
169
143
1511
13
29
155
1651
—
8
40
159
1639
30
194
133
1467
36
361
109
1201
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
1.9e-01
4.5e-01
1.6e+00
—
7.5e-01
5.8e-01
9.4e-02
cases:13.69%
controls:11.55%
cases:14.88%
controls:10.06%
cases:7.74%
controls:1.73%
—
—
cases:4.79%
controls:2.32%
cases:19.02%
controls:11.62%
cases:24.83%
controls:23.11%
23
194
145
1486
25
169
143
1511
13
29
155
1651
—
8
39
159
1640
31
193
132
1468
36
361
109
1201
Cathetrisation of vein
TPH04 [2001309597]
8.4e-01
—
—
—
—
1.9e+00
1.6e+00
cases:4.17%
controls:1.85%
—
—
—
—
—
—
—
—
cases:3.68%
controls:0.54%
cases:8.28%
controls:1.86%
7
31
161
1649
—
—
—
—
6
9
157
1652
12
29
133
1533
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
3.5e-01
9.1e-01
—
—
—
1.5e+00
6.3e-01
cases:4.76%
controls:3.39%
cases:6.55%
controls:2.74%
—
—
—
—
—
—
cases:10.43%
controls:2.47%
cases:13.10%
controls:7.43%
8
57
160
1623
11
46
157
1634
—
—
—
17
41
146
1620
19
116
126
1446
INR in Blood by Coagulation assay
34714-6 [3032080]
4.5e-01
7.0e-01
—
—
1.3e+00
1.5e+00
6.6e-01
cases:4.76%
controls:3.10%
cases:5.36%
controls:2.74%
—
—
—
—
cases:2.99%
controls:0.83%
cases:7.98%
controls:1.93%
cases:11.72%
controls:6.40%
8
52
160
1628
9
46
159
1634
—
—
5
14
162
1665
13
32
150
1629
17
100
128
1462
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.90%
controls:1.73%
—
—
—
—
—
—
10
27
135
1535
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
1.1e-01
8.0e-01
—
—
—
1.4e+00
5.3e-01
cases:4.76%
controls:4.29%
cases:4.76%
controls:2.20%
—
—
—
—
—
—
cases:8.59%
controls:2.23%
cases:13.79%
controls:8.58%
8
72
160
1608
8
37
160
1643
—
—
—
14
37
149
1624
20
134
125
1428
ambroxol; oral
R05CB06 [21603385]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.66%
controls:2.56%
—
—
—
—
—
—
14
40
131
1522
ibuprofen
R02AX02 [1588667]
6.3e-01
7.0e-01
—
—
6.4e-01
1.7e-01
1.5e-01
cases:39.88%
controls:26.19%
cases:20.83%
controls:11.61%
—
—
—
—
cases:2.99%
controls:1.61%
cases:15.34%
controls:13.31%
cases:35.86%
controls:32.59%
67
440
101
1240
35
195
133
1485
—
—
5
27
162
1652
25
221
138
1440
52
509
93
1053
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
6.3e-01
7.0e-01
—
—
6.4e-01
1.7e-01
1.5e-01
cases:39.88%
controls:26.19%
cases:20.83%
controls:11.61%
—
—
—
—
cases:2.99%
controls:1.61%
cases:15.34%
controls:13.31%
cases:35.86%
controls:32.59%
67
440
101
1240
35
195
133
1485
—
—
5
27
162
1652
25
221
138
1440
52
509
93
1053
Vascular Surgery
77 [38004496]
1.2e+00
—
—
—
—
1.7e+00
1.3e+00
cases:4.17%
controls:1.31%
—
—
—
—
—
—
—
—
cases:3.68%
controls:0.66%
cases:8.97%
controls:2.56%
7
22
161
1658
—
—
—
—
6
11
157
1650
13
40
132
1522
ebastine; oral
R06AX22 [21603521]
1.2e+00
—
—
—
—
—
—
cases:7.74%
controls:2.44%
—
—
—
—
—
—
—
—
—
—
—
—
13
41
155
1639
—
—
—
—
—
—
Person consulting for explanation of investigation findings
Z71.2 [45552100]
2.6e-01
—
—
—
—
—
1.2e+00
cases:2.98%
controls:2.32%
—
—
—
—
—
—
—
—
—
—
cases:8.97%
controls:2.94%
5
39
163
1641
—
—
—
—
—
13
46
132
1516
Emergency Room and Inpatient Visit
ERIP [262]
—
—
—
—
—
1.4e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:3.68%
controls:0.90%
cases:10.34%
controls:3.46%
—
—
—
—
—
6
15
157
1646
15
54
130
1508
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
4.4e-01
—
—
—
—
—
1.2e+00
cases:3.57%
controls:2.32%
—
—
—
—
—
—
—
—
—
—
cases:12.41%
controls:4.23%
6
39
162
1641
—
—
—
—
—
18
66
127
1496
ranitidine bismuth citrate; oral
A02BA07 [21600088]
1.1e+00
—
—
—
—
—
1.1e+00
cases:7.74%
controls:2.62%
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:1.60%
13
44
155
1636
—
—
—
—
—
7
25
138
1537
ranitidine; oral, parenteral
A02BA02 [21600083]
1.1e+00
—
—
—
—
—
1.1e+00
cases:7.74%
controls:2.62%
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:1.60%
13
44
155
1636
—
—
—
—
—
7
25
138
1537
fusidic acid; ointment
D06AX01 [21602062]
8.7e-01
—
—
—
—
—
1.1e+00
cases:5.36%
controls:2.32%
—
—
—
—
—
—
—
—
—
—
cases:8.97%
controls:3.14%
9
39
159
1641
—
—
—
—
—
13
49
132
1513
fusidic acid
D09AA02 [21602265]
8.7e-01
—
—
—
—
—
1.1e+00
cases:5.36%
controls:2.32%
—
—
—
—
—
—
—
—
—
—
cases:8.97%
controls:3.14%
9
39
159
1641
—
—
—
—
—
13
49
132
1513
More than one and less than three hours
ZXE10 [2001311401]
5.7e-01
—
—
—
—
1.1e+00
1.1e+00
cases:7.74%
controls:4.52%
—
—
—
—
—
—
—
—
cases:4.29%
controls:1.51%
cases:15.17%
controls:5.57%
13
76
155
1604
—
—
—
—
7
25
156
1636
22
87
123
1475
roxithromycin; oral
J01FA06 [21602974]
1.1e+00
5.6e-01
—
—
—
—
5.4e-01
cases:14.88%
controls:5.71%
cases:2.98%
controls:1.73%
—
—
—
—
—
—
—
—
cases:8.97%
controls:5.44%
25
96
143
1584
5
29
163
1651
—
—
—
—
13
85
132
1477
clindamycin; oral, parenteral
J01FF01 [21602985]
7.7e-01
1.5e+00
—
—
—
1.4e+00
1.0e+00
cases:5.95%
controls:2.86%
cases:4.76%
controls:1.13%
—
—
—
—
—
—
cases:3.07%
controls:0.78%
cases:10.34%
controls:3.97%
10
48
158
1632
8
19
160
1661
—
—
—
5
13
158
1648
15
62
130
1500
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
8.8e-01
-1.0e+50
—
—
-1.0e+50
9.5e-01
9.9e-01
cases:9.52%
controls:4.17%
cases:0.00%
controls:1.55%
—
—
—
—
cases:0.00%
controls:0.30%
cases:3.07%
controls:1.20%
cases:13.10%
controls:5.31%
16
70
152
1610
0
26
168
1654
—
—
0
5
167
1674
5
20
158
1641
19
83
126
1479
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
4.3e-01
—
—
—
—
—
9.6e-01
cases:9.52%
controls:6.43%
—
—
—
—
—
—
—
—
—
—
cases:17.24%
controls:7.36%
16
108
152
1572
—
—
—
—
—
25
115
120
1447
combinations of corticosteroids
D07AB30 [21602118]
9.6e-01
6.3e-01
-1.0e+50
—
-1.0e+50
6.8e-01
6.8e-01
cases:20.24%
controls:8.87%
cases:5.95%
controls:3.27%
cases:0.00%
controls:0.36%
—
—
cases:0.00%
controls:0.36%
cases:6.13%
controls:3.19%
cases:17.93%
controls:9.99%
34
149
134
1531
10
55
158
1625
0
6
168
1674
—
0
6
167
1673
10
53
153
1608
26
156
119
1406
combinations of corticosteroids
D07XB30 [21602188]
9.6e-01
6.3e-01
-1.0e+50
—
-1.0e+50
6.8e-01
6.8e-01
cases:20.24%
controls:8.87%
cases:5.95%
controls:3.27%
cases:0.00%
controls:0.36%
—
—
cases:0.00%
controls:0.36%
cases:6.13%
controls:3.19%
cases:17.93%
controls:9.99%
34
149
134
1531
10
55
158
1625
0
6
168
1674
—
0
6
167
1673
10
53
153
1608
26
156
119
1406
Orthopedic Surgery
20 [38004465]
4.0e-01
8.1e-01
—
—
—
6.9e-01
9.4e-01
cases:14.88%
controls:10.54%
cases:10.12%
controls:4.76%
—
—
—
—
—
—
cases:9.20%
controls:4.82%
cases:29.66%
controls:14.15%
25
177
143
1503
17
80
151
1600
—
—
—
15
80
148
1581
43
221
102
1341
Ophthalmology
18 [38004463]
6.2e-01
7.5e-01
1.4e+00
—
1.2e+00
7.2e-01
8.6e-01
cases:20.24%
controls:12.02%
cases:11.31%
controls:5.65%
cases:2.98%
controls:0.71%
—
—
cases:2.99%
controls:0.89%
cases:10.43%
controls:5.36%
cases:28.97%
controls:14.66%
34
202
134
1478
19
95
149
1585
5
12
163
1668
—
5
15
162
1664
17
89
146
1572
42
229
103
1333
Venous insufficiency (chronic)(peripheral)
I87.2 [45552867]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
0
6
163
1655
—
Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma
93769-8 [1002102]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
145
1557
insulin lispro; parenteral
A10AD04 [21600732]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
0
5
168
1675
—
—
—
—
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
145
1557
One-surface restoration
SFA10 [2001310358]
7.4e-01
7.2e-01
—
—
—
2.3e-01
3.7e-01
cases:9.52%
controls:4.76%
cases:4.76%
controls:2.38%
—
—
—
—
—
—
cases:3.68%
controls:2.95%
cases:13.79%
controls:9.92%
16
80
152
1600
8
40
160
1640
—
—
—
6
49
157
1612
20
155
125
1407
Acute cystitis
N30.0 [45601724]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
0
5
168
1675
—
—
—
—
—
Other reason for encounter NEC
-69 [2002000140]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
6
145
1556
Upper respiratory infection acute
R74 [2002000942]
6.7e-01
-1.0e+50
—
—
—
—
2.5e-01
cases:2.98%
controls:1.55%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
cases:4.14%
controls:3.27%
5
26
163
1654
0
10
168
1670
—
—
—
—
6
51
139
1511
Functional dysphonia
R49.01 [2000503597]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
168
1675
—
—
—
—
—
—
lactulose; oral
A06AD11 [21600571]
1.2e+00
—
—
—
—
—
9.8e-01
cases:4.17%
controls:1.31%
—
—
—
—
—
—
—
—
—
—
cases:6.21%
controls:2.43%
7
22
161
1658
—
—
—
—
—
9
38
136
1524
Cryotherapy
ZXC50 [2001311370]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.42%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
0
7
168
1673
0
6
168
1674
—
—
—
—
0
5
145
1557
Other somatoform disorders
F45.8 [45600750]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
168
1674
—
—
—
—
—
—
Other angina pectoris unspecified coronary artery status
I20.89 [2000502401]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
145
1555
Medical Oncology
90 [38004507]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
11
168
1669
—
0
13
167
1666
—
—
Mild cognitive disorder
F06.7 [45605450]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
168
1675
—
—
—
—
—
—
rofecoxib; oral
M01AH02 [21603993]
9.8e-01
—
—
—
—
—
1.3e+00
cases:3.57%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:1.22%
6
23
162
1657
—
—
—
—
—
6
19
139
1543
Irradiated enamel
K03.80 [2000502698]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
145
1555
glucagon; nasal, parenteral
H04AA01 [21602778]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
0
10
168
1670
—
—
—
—
0
5
163
1656
—
carbamazepine; oral, rectal
N03AF01 [21604417]
—
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.48%
cases:0.00%
controls:0.30%
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
0
8
168
1672
0
5
168
1675
—
—
0
10
163
1651
—
Hand Surgery
40 [38004480]
7.5e-01
—
—
—
—
—
7.9e-01
cases:3.57%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:2.24%
6
29
162
1651
—
—
—
—
—
7
35
138
1527
Unstable angina
I20.09 [2000502389]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
168
1672
—
—
—
—
—
—
indometacin
C01EB03 [21600365]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
0
7
168
1673
—
—
—
—
0
8
145
1554
Adhesive capsulitis of shoulder
M75.0 [45533931]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
145
1555
prednisolone
S01BA04 [21603621]
1.2e+00
—
—
—
—
—
—
cases:2.98%
controls:0.89%
—
—
—
—
—
—
—
—
—
—
—
—
5
15
163
1665
—
—
—
—
—
—
Adjustment and management of cardiac devices
Z45.0 [45595515]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
6
145
1556
Examination and observation for other specified reasons
Z04.8 [45552063]
1.4e+00
—
—
—
—
—
—
cases:2.98%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
5
12
163
1668
—
—
—
—
—
—
Foot/toe symptom/complaint
L17 [2002000641]
—
—
—
—
—
—
3.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:3.46%
—
—
—
—
—
—
7
54
138
1508
bupivacaine, combinations
N01BB51 [21604240]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
168
1673
—
—
—
—
—
—
phenoxymethylpenicillin; oral
J01CE02 [21602842]
2.8e-01
9.0e-01
—
—
—
9.6e-01
3.3e-01
cases:13.69%
controls:10.71%
cases:5.95%
controls:2.50%
—
—
—
—
—
—
cases:6.75%
controls:2.71%
cases:17.24%
controls:13.00%
23
180
145
1500
10
42
158
1638
—
—
—
11
45
152
1616
25
203
120
1359
Other difficulties with micturition
R39.1 [45534441]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
145
1555
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
1.9e-01
-2.5e-02
1.2e+00
—
—
2.1e-02
-2.3e-02
cases:12.50%
controls:10.60%
cases:7.74%
controls:7.92%
cases:2.98%
controls:0.95%
—
—
—
—
cases:9.20%
controls:9.03%
cases:21.38%
controls:21.77%
21
178
147
1502
13
133
155
1547
5
16
163
1664
—
—
15
150
148
1511
31
340
114
1222
metoprolol and felodipine
C07FB02 [21601742]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.48%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
0
8
168
1672
0
6
168
1674
—
—
—
—
—
diclofenac
D11AX18 [21602355]
1.1e+00
—
—
—
—
—
—
cases:3.57%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
—
—
6
21
162
1659
—
—
—
—
—
—
Primary arthrosis of other joints
M19.0 [45601353]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:1.34%
—
—
—
—
—
—
6
21
139
1541
Localized oedema
R60.0 [45597193]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.58%
—
—
—
—
—
—
5
9
140
1553
hydrocortisone
C05AA01 [21601608]
4.5e-01
5.8e-01
—
—
—
1.2e+00
4.1e-01
cases:10.12%
controls:6.73%
cases:3.57%
controls:2.02%
—
—
—
—
—
—
cases:4.91%
controls:1.57%
cases:11.03%
controls:7.62%
17
113
151
1567
6
34
162
1646
—
—
—
8
26
155
1635
16
119
129
1443
Tinnitus
H93.1 [45543152]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
0
6
168
1674
0
5
168
1675
—
—
—
—
—
X-ray examination of the lungs in one projection
GD1PA [2001303645]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.58%
—
—
—
—
—
—
5
9
140
1553
Gonarthrosis [arthrosis of knee]
M17 [45601350]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.65%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
0
11
168
1669
0
10
168
1670
—
—
—
0
9
163
1652
—
Asthma, unspecified
J45.9 [45562456]
—
1.5e+00
—
—
—
—
2.5e-01
—
—
cases:3.57%
controls:0.83%
—
—
—
—
—
—
—
—
cases:4.14%
controls:3.27%
—
6
14
162
1666
—
—
—
—
6
51
139
1511
Emergency Medicine
93 [38004510]
1.6e-01
9.6e-01
—
—
-1.0e+50
9.7e-01
1.4e-01
cases:5.36%
controls:4.58%
cases:7.14%
controls:2.86%
—
—
—
—
cases:0.00%
controls:0.36%
cases:7.98%
controls:3.19%
cases:11.72%
controls:10.37%
9
77
159
1603
12
48
156
1632
—
—
0
6
167
1673
13
53
150
1608
17
162
128
1400
Constipation
D12 [2002000311]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
6
145
1556
Nutrition survey
SPAT1139 [2001700240]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
6
145
1556
Lateral epicondylitis
M77.1 [45572551]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
0
11
145
1551
zopiclone; oral
N05CF01 [21604654]
4.5e-01
8.8e-01
—
—
1.2e+00
8.5e-01
4.6e-01
cases:10.12%
controls:6.67%
cases:9.52%
controls:4.17%
—
—
—
—
cases:3.59%
controls:1.07%
cases:9.20%
controls:4.15%
cases:11.72%
controls:7.75%
17
112
151
1568
16
70
152
1610
—
—
6
18
161
1661
15
69
148
1592
17
121
128
1441
levodopa and decarboxylase inhibitor; oral
N04BA02 [21604465]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
0
6
168
1674
0
6
168
1674
—
—
—
0
6
163
1655
—
fludrocortisone and antiinfectives
S03CA05 [21605209]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
145
1557
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
2.3e+00
—
—
—
—
—
1.1e+00
cases:2.98%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:1.15%
5
5
163
1675
—
—
—
—
—
5
18
140
1544
Examination of ears and hearing
Z01.1 [45547279]
6.7e-01
—
—
—
—
-1.0e+50
—
cases:2.98%
controls:1.55%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
5
26
163
1654
—
—
—
—
0
14
163
1647
—
fluconazole; oral, parenteral
J02AC01 [21603080]
4.6e-01
9.5e-01
—
—
—
5.5e-01
6.6e-01
cases:13.10%
controls:8.69%
cases:5.95%
controls:2.38%
—
—
—
—
—
—
cases:4.91%
controls:2.89%
cases:13.79%
controls:7.62%
22
146
146
1534
10
40
158
1640
—
—
—
8
48
155
1613
20
119
125
1443
oxazepam; oral
N05BA04 [21604569]
8.0e-01
1.6e-01
-1.0e+50
—
—
6.2e-01
1.3e-01
cases:7.74%
controls:3.63%
cases:2.98%
controls:2.56%
cases:0.00%
controls:0.42%
—
—
—
—
cases:4.29%
controls:2.35%
cases:6.21%
controls:5.51%
13
61
155
1619
5
43
163
1637
0
7
168
1673
—
—
7
39
156
1622
9
86
136
1476
enalapril; oral, parenteral
C09AA02 [21601786]
6.0e-01
4.7e-01
—
—
—
—
2.0e-01
cases:7.14%
controls:4.05%
cases:3.57%
controls:2.26%
—
—
—
—
—
—
—
—
cases:4.83%
controls:3.97%
12
68
156
1612
6
38
162
1642
—
—
—
—
7
62
138
1500
Tension-type headache
G44.2 [45581495]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
6
168
1674
—
—
—
—
—
Hand/finger symptom/complaint
L12 [2002000636]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
168
1668
—
—
—
—
—
—
Monitoring the use of the aid
R5140 [2001310249]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.83%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
0
14
168
1666
0
5
168
1675
—
—
—
0
7
163
1654
—
Procollagen type III.N-terminal propeptide [Mass/volume] in Serum
71792-6 [42869547]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.00%
—
—
—
—
—
—
5
0
140
1562
Acute tonsillitis, unspecified
J03.9 [45576942]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
168
1674
—
—
—
—
—
—
Other hypothyroidism
E03 [45581337]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
12
145
1550
pioglitazone; oral
A10BG03 [21600782]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.42%
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
0
7
168
1673
0
5
168
1675
—
—
—
—
0
5
145
1557
fluticasone furoate; nasal
R01AD12 [21605053]
-9.7e-03
—
-1.0e+50
—
—
4.8e-01
7.6e-01
cases:6.55%
controls:6.61%
—
—
cases:0.00%
controls:0.42%
—
—
—
—
cases:3.07%
controls:1.93%
cases:13.79%
controls:6.98%
11
111
157
1569
—
0
7
168
1673
—
—
5
32
158
1629
20
109
125
1453
Periodic health check-up of children and adolescents
SPAT1315 [2001700416]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
—
—
—
—
0
12
145
1550
Treatment plan or consultation
WZC00 [2001310885]
8.6e-02
—
—
—
—
—
4.3e-02
cases:2.98%
controls:2.74%
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:3.97%
5
46
163
1634
—
—
—
—
—
6
62
139
1500
Throat symptom/complaint
R21 [2002000891]
—
-1.0e+50
—
—
—
—
7.1e-01
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
cases:3.45%
controls:1.73%
—
0
5
168
1675
—
—
—
—
5
27
140
1535
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:1.79%
—
—
—
—
—
—
7
28
138
1534
Fall on same level involving ice and snow
W00 [45756242]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
168
1673
—
—
—
—
—
—
Paraesthesia of skin
R20.2 [45568120]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
6
145
1556
Health maint/preventive medicine
A98 [2002000231]
1.5e-01
2.5e-01
4.4e-01
—
9.9e-01
1.5e-01
2.4e-01
cases:17.26%
controls:15.24%
cases:15.48%
controls:12.44%
cases:3.57%
controls:2.32%
—
—
cases:6.59%
controls:2.56%
cases:15.34%
controls:13.55%
cases:33.79%
controls:28.62%
29
256
139
1424
26
209
142
1471
6
39
162
1641
—
11
43
156
1636
25
225
138
1436
49
447
96
1115
Obesity
T82 [2002001125]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
6
145
1556
Chron obstructive pulmonary disease
R95 [2002000960]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
0
9
145
1553
liraglutide; parenteral
A10BJ02 [1123630]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
6
145
1556
Malignant tumor of the lower outer quadrant of the mammary gland, ductal tumor
C50.51 [2000501006]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
145
1555
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
351 [2001600312]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
168
1673
—
—
—
—
—
—
Curettage of cervix and body of uterus
LCA13 [2001306553]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
0
7
163
1654
—
Functional capacity evaluation
443351003 [40481051]
—
—
—
—
—
—
7.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:2.43%
—
—
—
—
—
—
7
38
138
1524
Unspecified fall
W19 [45756257]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.36%
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
0
6
168
1674
0
8
168
1672
—
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 [2002330110]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
6
168
1674
—
—
—
—
—
Calculus of gallbladder with acute cholecystitis
K80.0 [45586735]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
168
1675
—
—
—
—
—
—
Diabetes non-insulin dependent
T90 [2002001131]
—
—
-1.0e+50
—
-1.0e+50
—
-1.1e-01
—
—
—
—
cases:0.00%
controls:0.65%
—
—
cases:0.00%
controls:0.66%
—
—
cases:4.14%
controls:4.61%
—
—
0
11
168
1669
—
0
11
167
1668
—
6
72
139
1490
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
—
2.1e+00
—
—
—
—
1.5e+00
—
—
cases:2.98%
controls:0.36%
—
—
—
—
—
—
—
—
cases:5.52%
controls:1.28%
—
5
6
163
1674
—
—
—
—
8
20
137
1542
Pneumonia
R81 [2002000949]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
0
6
145
1556
PEF monitoring instruction
SPAT1058 [2001700159]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
—
—
0
18
145
1544
dexbrompheniramine, combinations
R06AB56 [21603469]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
0
5
168
1675
—
—
—
—
—
0
7
145
1555
Impacted cerumen
H61.2 [45562307]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
168
1673
—
—
—
—
—
—
Joint symptom/complaint NOS
L20 [2002000644]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
145
1557
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
T81.0 [45599741]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
9
168
1671
—
—
—
—
—
0
6
145
1556
methylprednisolone, combinations
H02BX01 [21602747]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
168
1673
—
—
—
—
—
—
Immunoglobulin light chains.free panel - Serum
57778-3 [40760888]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:4.29%
controls:0.00%
—
—
—
—
—
—
—
7
0
156
1661
—
X-ray mammography
HA1AA [2001303884]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
0
6
168
1674
—
—
—
0
8
163
1653
—
Tissue Pathology biopsy report
66121-5 [40768804]
—
2.8e-01
—
—
—
—
2.6e-01
—
—
cases:2.98%
controls:2.26%
—
—
—
—
—
—
—
—
cases:6.21%
controls:4.87%
—
5
38
163
1642
—
—
—
—
9
76
136
1486
azithromycin; oral, parenteral
J01FA10 [21602978]
4.0e-01
2.2e-01
—
—
—
4.8e-01
5.0e-01
cases:13.69%
controls:9.58%
cases:5.36%
controls:4.35%
—
—
—
—
—
—
cases:5.52%
controls:3.49%
cases:14.48%
controls:9.35%
23
161
145
1519
9
73
159
1607
—
—
—
9
58
154
1603
21
146
124
1416
rizatriptan; oral
N02CC04 [21604379]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.95%
cases:0.00%
controls:0.36%
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
0
16
168
1664
0
6
168
1674
—
—
—
0
9
163
1652
—
finasteride; oral
D11AX10 [21602350]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
—
0
9
168
1671
—
—
—
—
—
amoxicillin; oral, parenteral
J01CA04 [21602823]
4.4e-01
7.5e-01
—
—
—
3.0e-01
5.1e-01
cases:28.57%
controls:20.54%
cases:12.50%
controls:6.31%
—
—
—
—
—
—
cases:7.98%
controls:6.02%
cases:32.41%
controls:22.41%
48
345
120
1335
21
106
147
1574
—
—
—
13
100
150
1561
47
350
98
1212
vilanterol and fluticasone furoate
R03AK10 [43534841]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
cases:0.00%
controls:0.51%
—
—
—
—
—
0
5
163
1656
0
8
145
1554
ketoprofen; ointment
M02AA10 [21604046]
1.0e+00
-1.0e+50
—
—
—
-1.0e+50
—
cases:4.76%
controls:1.73%
cases:0.00%
controls:0.71%
—
—
—
—
—
—
cases:0.00%
controls:0.66%
—
—
8
29
160
1651
0
12
168
1668
—
—
—
0
11
163
1650
—
Periodontitis pronounced
K05.31 [2000502729]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
0
6
168
1674
—
—
—
—
0
5
163
1656
—
Glucose tolerance 2 hours panel - Serum or Plasma
72171-2 [43054914]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
—
—
—
—
0
6
168
1674
—
—
—
—
—
ketorolac
S01BC05 [21603643]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
145
1555
Obstetrics / Gynecology
16 [38004461]
3.6e-01
4.5e-01
—
—
1.3e+00
6.3e-01
2.8e-01
cases:22.62%
controls:16.96%
cases:10.12%
controls:6.67%
—
—
—
—
cases:4.19%
controls:1.13%
cases:11.66%
controls:6.56%
cases:19.31%
controls:15.30%
38
285
130
1395
17
112
151
1568
—
—
7
19
160
1660
19
109
144
1552
28
239
117
1323
metoprolol; oral, parenteral
C07AB02 [21601684]
-4.7e-01
—
—
—
—
-2.0e-01
4.0e-02
cases:3.57%
controls:5.60%
—
—
—
—
—
—
—
—
cases:3.68%
controls:4.46%
cases:5.52%
controls:5.31%
6
94
162
1586
—
—
—
—
6
74
157
1587
8
83
137
1479
Atherosclerotic cardiovascular disease, so described
I25.0 [45552783]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
168
1675
—
—
—
—
—
—
dexamethasone and antiinfectives
S03CA01 [21605206]
1.4e+00
—
—
—
—
—
-1.0e+50
cases:4.76%
controls:1.19%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.86%
8
20
160
1660
—
—
—
—
—
0
29
145
1533
Malignant tumor of the upper outer quadrant of the mammary gland, other or undeterminated histology
C50.49 [2000501004]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
0
5
168
1675
—
—
—
—
—
0
6
145
1556
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
1.7e-02
7.4e-01
—
—
—
8.8e-01
2.7e-01
cases:3.57%
controls:3.51%
cases:4.17%
controls:2.02%
—
—
—
—
—
—
cases:3.68%
controls:1.57%
cases:6.21%
controls:4.80%
6
59
162
1621
7
34
161
1646
—
—
—
6
26
157
1635
9
75
136
1487
chlorphenamine, combinations
R06AB54 [21603468]
-2.2e-01
—
—
—
—
—
—
cases:2.98%
controls:3.69%
—
—
—
—
—
—
—
—
—
—
—
—
5
62
163
1618
—
—
—
—
—
—
Feeling depressed
P03 [2002000800]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.30%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
0
5
168
1675
—
—
—
—
—
0
7
145
1555
Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep
18500-9 [3018006]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
0
7
163
1654
—
chlorhexidine
S02AA09 [21605155]
1.1e+00
—
—
—
—
—
8.2e-01
cases:4.17%
controls:1.43%
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:1.86%
7
24
161
1656
—
—
—
—
—
6
29
139
1533
Elevated blood-pressure reading, without diagnosis of hypertension
R03.0 [45553712]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
7
145
1555

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
66
81
12.77
54.08
3.3
1.8
11.17
4.18
iu/ml
0.84
26
22
53
58
12.89
46.55
1.6
1.3
1.37
2.71
u/ml
—
14
9
56
68
11.85
45.68
1.7
1.3
7.98
0.32
u/ml
—
6
5
52
59
12.32
44.43
1.6
1.3
7.74
2.90
u/ml
0.48
19
12
47
59
10.67
36.94
3.3
1.5
1.07
1.15
g/l
0.71
47
59
90
244
6.79
34.78
1.9
1.3
1324.59
501.45
titre
3.79
61
69
119
523
5.37
23.79
7.3
3.4
805.81
954.39
ng/l
0.51
110
441
113
518
4.61
20.30
20.5
5.6
—
—
—
0
0
125
682
4.25
16.14
6.9
3.8
6.36
6.31
ph
0.23
73
374
143
866
5.38
15.81
8.8
4.2
0.00
9.28
estimate
0.50
26
175
142
860
5.21
15.57
8.8
4.1
0.00
0.00
estimate
-0.00
26
166
130
743
4.31
15.35
20.7
5.9
60.44
57.55
%
2.46
130
705
130
743
4.31
15.35
22.5
5.9
2.73
2.87
%
0.37
130
691
130
745
4.29
15.24
22.7
6.0
8.93
8.62
%
0.73
130
694
129
741
4.19
14.94
22.9
5.9
0.72
0.73
%
0.02
129
684
142
874
5.04
14.88
9.0
4.2
0.00
0.00
estimate
-0.00
26
162
23
44
5.90
11.91
2.1
1.6
125.00
125.83
g/l
—
10
30
83
411
3.01
11.20
4.7
2.2
3.55
3.19
mg/l
0.54
78
357
40
127
3.82
11.17
9.1
4.6
0.25
0.65
%
0.96
24
39
79
385
2.99
10.91
8.6
4.4
1.01
1.02
kg/l
1.03
61
252
55
218
3.26
10.89
2.9
2.1
—
—
—
0
0
48
178
3.38
10.55
3.1
1.7
—
—
—
0
0
41
138
3.61
10.47
10.5
4.5
0.81
0.71
%
0.16
26
47
80
409
2.83
9.89
6.8
2.9
344.54
330.93
umol/l
0.49
70
346
128
840
3.20
9.81
12.7
7.5
1.22
1.22
mmol/l
0.23
117
720
41
144
3.44
9.76
3.0
1.5
—
—
—
0
0
45
170
3.25
9.52
1.9
2.0
339.23
388.38
nmol/l
0.77
40
162
74
371
2.78
9.40
5.2
2.7
2.86
5.89
e6/l
2.86
69
338
37
127
3.45
9.09
11.5
4.6
0.05
0.14
%
0.57
22
36
32
100
3.72
9.05
1.2
1.4
—
—
—
0
0
116
742
2.82
8.93
15.8
12.6
1.19
1.19
inr
0.03
99
600
78
417
2.62
8.54
6.5
4.2
—
—
—
0
0
39
144
3.22
8.50
2.1
3.2
71.05
73.26
e9/l
0.15
32
105
117
763
2.76
8.48
11.0
6.7
1.21
1.22
mmol/l
0.67
112
698
15
15
10.85
8.22
1.3
1.2
—
—
—
0
0
93
551
2.54
8.09
6.2
4.0
7.40
7.40
ph
0.20
74
396
90
527
2.52
8.00
6.7
3.4
12.70
23.39
e6/l
1.69
79
398
47
200
2.87
7.97
4.2
3.2
10.75
5.70
e9/l
0.33
41
175
41
162
3.03
7.93
1.4
1.4
—
—
—
0
0
85
488
2.50
7.85
9.4
4.3
0.00
0.00
estimate
-0.00
26
162
20
49
4.50
7.78
7.3
1.9
24.16
24.39
mmol/l
0.08
20
49
64
323
2.59
7.75
5.0
3.8
358.19
134.22
ng/l
0.54
52
261
103
650
2.51
7.69
8.9
4.1
0.00
0.00
estimate
-0.00
24
134
15
18
9.03
7.50
1.3
1.2
—
—
—
0
0
97
603
2.44
7.38
8.9
4.1
37.82
82.75
e6/l
0.64
81
410
11
7
16.68
7.33
1.8
1.0
—
—
—
0
0
79
452
2.41
7.19
6.2
3.2
0.07
0.37
e6/l
4.49
67
324
35
134
3.04
7.11
11.4
5.1
0.00
0.14
%
0.64
19
36
32
120
3.06
6.72
3.1
2.9
—
—
—
0
0
24
77
3.47
6.46
1.3
1.3
—
—
—
0
0
51
249
2.51
6.46
1.6
1.2
—
—
—
0
0
18
36
5.47
6.40
1.3
2.0
—
—
—
0
0
9
6
15.74
5.97
2.9
1.5
17.56
117.50
e6/l
—
9
6
43
201
2.53
5.92
1.3
1.5
—
—
—
0
0
65
366
2.27
5.90
2.0
1.4
1.94
2.44
g/l
1.47
50
209
10
9
11.72
5.87
2.0
1.1
—
—
—
0
0
10
9
11.72
5.87
2.2
1.2
—
—
—
0
0
15
28
5.77
5.69
1.5
1.3
—
—
—
0
0
63
355
2.24
5.67
15.7
5.5
—
—
—
0
0
9
7
13.49
5.65
2.7
1.9
39.44
38.96
%
—
9
7
17
48
3.83
5.48
2.5
5.2
4.38
3.26
ratio
0.15
12
25
38
175
2.51
5.37
10.8
10.3
7.44
7.42
ph
0.71
29
112
75
464
2.11
5.25
7.3
3.5
0.00
0.00
estimate
-0.00
25
130
23
84
3.01
5.02
3.3
2.3
0.00
0.04
estimate
—
5
27
81
523
2.06
5.00
9.9
6.5
—
—
—
0
0
31
135
2.59
4.89
6.9
3.6
—
—
—
0
0
90
609
2.03
4.83
3.7
3.3
2.37
2.37
mmol/l
0.00
85
552
24
92
2.88
4.81
4.8
9.3
—
—
—
0
0
54
304
2.14
4.75
5.4
3.0
484.78
495.17
mosm/kgh2o
0.14
49
264
13
26
5.33
4.74
7.2
1.9
86.90
89.71
%
0.52
13
26
19
64
3.22
4.73
6.6
4.0
—
—
—
0
0
13
27
5.13
4.60
3.2
3.5
—
—
—
0
0
42
216
2.26
4.60
2.9
1.5
—
—
—
0
0
99
702
2.00
4.56
26.6
11.7
0.00
0.00
e9/l
0.43
94
565
14
33
4.53
4.44
6.9
2.4
7.44
7.86
kpa
0.52
14
33
18
61
3.18
4.44
1.3
1.5
267.10
282.12
ug/g
—
10
36
79
523
1.96
4.39
3.1
2.6
58.28
55.72
u/l
0.31
72
488
12
26
4.89
4.14
2.5
1.6
—
—
—
0
0
16
54
3.17
3.97
2.7
1.9
1.83
1.54
mg/l
0.69
16
47
10
19
5.52
3.89
2.8
4.9
—
—
—
0
0
43
239
2.07
3.83
5.5
3.3
4.02
3.61
e6/l
0.08
27
108
46
263
2.03
3.80
7.2
3.6
0.82
0.80
mmol/l
0.43
41
248
10
21
4.99
3.61
1.2
1.4
—
—
—
0
0
8
13
6.40
3.54
1.4
4.7
531.62
932.15
mg
—
8
13
32
164
2.18
3.49
3.1
2.2
0.00
0.08
estimate
—
8
36
11
27
4.28
3.46
1.2
1.0
—
—
—
0
0
14
50
2.96
3.17
6.6
4.8
24.06
25.49
mmol/l
0.91
14
50
10
25
4.18
3.14
7.7
2.4
4.71
4.81
e9/l
—
10
25
96
728
1.74
3.10
3.3
2.9
—
—
estimate
—
0
0
39
226
1.95
3.06
1.3
1.7
—
—
—
0
0
11
31
3.72
3.05
4.5
2.4
15.72
15.89
%
0.06
11
31
7
12
6.03
3.05
2.9
1.8
0.64
0.36
e9/l
—
7
12
6
9
6.86
2.89
1.0
5.0
81.50
271.78
nmol/l
—
6
9
9
24
3.90
2.71
3.1
1.5
—
—
—
0
0
9
24
3.90
2.71
3.1
1.5
—
—
—
0
0
9
24
3.90
2.71
3.1
1.5
—
—
—
0
0
9
24
3.90
2.71
3.1
1.5
—
—
—
0
0
75
548
1.67
2.65
5.1
3.4
—
—
—
0
0
38
229
1.85
2.63
13.4
6.3
102.89
103.79
mmol/l
0.53
38
229
5
7
7.32
2.56
1.2
1.0
—
—
—
0
0
5
7
7.32
2.56
1.2
1.0
—
—
—
0
0
44
280
1.77
2.55
1.7
1.7
1225.26
1260.22
nmol/l
0.10
36
204
20
96
2.23
2.55
15.1
9.2
22.96
24.54
mmol/l
1.14
20
96
7
16
4.52
2.50
1.4
1.3
—
—
—
0
0
25
136
1.98
2.33
16.3
8.0
—
—
—
0
0
13
54
2.53
2.26
3.9
2.8
333.13
159.38
mg/l
—
8
13
94
749
1.58
2.21
2.4
2.1
100.22
99.70
pmol/l
0.04
61
351
7
19
3.80
2.17
2.0
1.8
—
—
—
0
0
19
98
2.06
2.05
14.6
7.6
25.38
24.76
mmol/l
0.21
19
98
8
26
3.18
2.04
6.1
2.9
—
—
—
0
0
9
32
2.91
2.03
8.4
2.9
7.54
8.64
kpa
—
9
32
37
538
0.60
2.01
2.7
3.5
—
—
—
0
0
19
99
2.04
2.00
6.0
3.0
24.25
24.72
mmol/l
0.29
19
99
10
39
2.66
1.98
8.5
2.3
60.30
61.48
%
—
10
39
10
39
2.66
1.98
1.2
1.3
—
—
—
0
0
28
169
1.79
1.92
5.6
3.3
7.39
7.39
ph
0.00
18
102
7
22
3.27
1.90
1.0
1.0
—
—
—
0
0
57
419
1.55
1.84
1.4
1.3
0.43
1.65
u/ml
—
10
115
48
340
1.58
1.82
1.3
1.4
74.93
37.92
iu/ml
0.37
15
121
19
103
1.95
1.80
17.7
9.0
1.07
1.44
%
1.34
19
103
6
18
3.42
1.76
1.2
3.7
—
—
—
0
0
18
98
1.94
1.69
1.7
1.2
—
—
—
0
0
78
624
1.47
1.65
7.9
4.1
25.31
122.89
ng/l
0.56
59
451
18
99
1.92
1.65
18.3
9.3
0.56
0.66
%
0.46
18
99
8
33
2.49
1.56
1.9
1.9
6.57
7.28
pmol/l
—
8
33
66
517
1.46
1.53
2.9
2.5
—
—
—
0
0
23
142
1.72
1.48
1.2
1.2
—
—
—
0
0
5
16
3.19
1.45
1.0
1.3
—
—
—
0
0
6
22
2.79
1.45
1.8
1.5
5.53
170.98
u/ml
—
6
22
16
90
1.86
1.38
1.6
3.4
4.08
4.50
pmol/l
1.01
16
75
15
83
1.89
1.36
2.7
2.5
—
—
—
0
0
156
1466
1.90
1.33
45.4
16.8
18.92
21.30
mg/l
0.62
148
1195
6
24
2.55
1.31
1.3
1.4
31.83
32.08
pg
—
6
24
6
26
2.35
1.19
1.7
1.4
—
—
—
0
0
10
50
2.06
1.19
2.3
2.6
—
—
—
0
0
5
20
2.54
1.16
1.4
1.1
—
—
—
0
0
14
81
1.79
1.13
6.6
3.5
36.88
36.94
°c
0.32
14
81
7
32
2.24
1.09
8.7
2.9
5.57
5.05
kpa
—
7
32
9
48
1.92
1.02
7.8
2.6
7.41
7.42
ph
—
9
48
7
35
2.04
1.01
7.4
2.1
63.20
59.29
%
—
7
35
5
23
2.21
0.98
1.2
1.2
0.22
0.19
nmol/l
—
5
15
5
23
2.21
0.98
3.6
2.7
90.70
90.20
%
—
5
23
56
672
0.75
0.96
2.0
2.0
1.38
1.30
mmol/l
0.44
45
560
6
27
2.27
0.94
1.3
8.8
5.98
6.52
mmol/l
—
6
20
65
551
1.29
0.84
3.3
3.2
66.29
39.40
mg/l
0.48
37
331
66
563
1.28
0.81
3.7
3.7
20.96
7.35
mg/mmol
0.58
38
322
15
100
1.55
0.76
1.5
1.3
—
47.97
—
0
8
5
24
2.12
0.75
1.0
1.1
—
—
—
0
0
5
24
2.12
0.75
1.0
1.1
—
—
—
0
0
66
569
1.26
0.73
3.4
3.1
5.57
7.17
mmol/l
3.06
58
467
17
118
1.49
0.72
12.6
3.8
—
—
—
0
0
46
388
1.26
0.60
2.4
1.7
1.09
1.22
mg/l
0.12
39
311
38
315
1.27
0.58
1.3
1.3
1.29
13.47
u/ml
2.84
12
123
141
1465
0.77
0.55
5.3
5.5
5.70
5.95
mmol/l
1.28
136
1347
134
1399
0.79
0.53
4.6
4.5
1.22
1.25
mmol/l
0.26
125
1265
129
1223
1.24
0.51
46.3
21.0
14.79
13.73
%
11.88
129
1214
7
106
0.65
0.50
1.0
1.3
—
—
—
0
0
11
76
1.48
0.49
1.7
3.0
23.00
2281.38
u/ml
0.68
11
67
7
46
1.54
0.49
7.9
3.3
4.06
3.88
mmol/l
—
7
46
145
1496
0.78
0.46
5.8
6.3
2.58
2.71
mmol/l
0.94
137
1371
19
148
1.32
0.46
5.2
2.6
6.21
6.14
ph
0.16
14
99
129
1230
1.21
0.44
5.5
4.9
15.36
14.96
pmol/l
1.07
123
1118
8
59
1.37
0.41
1.3
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
1.21
—
0
9
0
16
0.00
0.41
0.0
2.0
—
13.60
—
0
10
21
169
1.28
0.41
1.5
1.4
—
—
—
0
0
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
4.01
—
0
11
39
338
1.20
0.40
2.0
1.7
422.90
496.70
pmol/l
0.85
34
272
0
18
0.00
0.40
0.0
1.8
—
—
—
0
0
0
18
0.00
0.40
0.0
1.0
—
2.01
—
0
9
0
19
0.00
0.39
0.0
1.0
—
1.72
—
0
9
25
208
1.24
0.38
1.7
1.3
—
—
—
0
0
6
47
1.29
0.32
26.3
12.1
—
—
—
0
0
125
1204
1.15
0.29
50.4
22.2
325.16
330.79
g/l
9.20
125
1204
9
119
0.74
0.28
1.7
1.3
—
—
—
0
0
144
1471
0.85
0.24
5.3
5.4
4.58
4.71
mmol/l
0.71
137
1350
5
40
1.26
0.22
1.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
1.00
—
0
10
0
10
0.00
0.21
0.0
2.8
—
28.80
—
0
5
0
10
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
7.68
—
0
7
0
14
0.00
0.20
0.0
1.1
—
0.34
—
0
6
139
1418
0.89
0.19
7.5
6.1
2.05
1.94
mu/l
0.58
134
1306
144
1465
0.88
0.17
5.1
5.3
1.56
1.57
mmol/l
0.06
135
1339
5
66
0.75
0.17
1.2
1.4
—
—
—
0
0
157
1550
1.20
0.16
50.9
22.3
75.26
73.22
umol/l
0.41
157
1532
6
58
1.04
0.08
1.2
1.4
40.27
31.31
iu/l
—
6
52
9
83
1.09
0.07
1.6
1.9
—
—
—
0
0
8
92
0.86
0.07
2.3
1.6
—
—
—
0
0
157
1580
0.90
0.05
62.5
25.4
29.55
30.28
pg
4.99
157
1565
157
1580
0.90
0.05
64.5
26.0
39.42
39.88
%
0.74
157
1564
157
1580
0.90
0.05
62.9
25.6
6.99
6.60
e9/l
1.46
157
1548
157
1580
0.90
0.05
63.0
25.6
4.37
4.42
e12/l
0.72
157
1546
157
1580
0.90
0.05
64.0
25.8
128.15
132.80
g/l
3.94
157
1563
39
403
0.96
0.05
1.4
1.4
—
—
—
0
0
157
1579
0.91
0.04
63.3
25.6
266.05
256.48
e9/l
0.89
157
1554
157
1579
0.91
0.04
62.7
25.5
90.93
91.38
fl
0.59
157
1564
66
669
0.98
0.02
2.4
2.2
—
—
—
0
0
150
1506
0.96
0.00
32.1
14.5
—
—
—
0
0
10
97
1.03
0.00
5.0
2.4
0.66
0.61
%
—
10
97
21
207
1.02
0.00
1.1
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
0.00
—
0
7
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
11.9
—
905.14
—
0
7
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
10
100
1.00
-0.00
5.0
2.4
0.76
1.18
%
—
10
100
5
56
0.89
-0.00
1.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
1.20
—
0
5

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: M13_PROGRESSIVE_SYSTEMIC_SCLEROSIS – Progressive systemic sclerosis

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).